

FIJI ESSENTIAL MEDICINES LIST

4th Edition (April 2015)

For the latest version of this document visit the Ministry of Health and Medical Services, Fiji Pharmaceutical & Biomedical Services Centre

Website: http://www.health.gov.fj/?page_id=192#15





FIJI ESSENTIAL MEDICINES LIST

4th Edition (April 2015)



For the latest version of this document visit the Ministry of Health and Medical Services, Fiji Pharmaceutical & Biomedical Services Centre
Website: http://www.health.gov.fj/?page_id=192#15

Foreword

The 4th edition of the Fiji Essential Medicines List (EML) has been revised from the 3rd edition and has been compiled and reviewed by the Essential Medicines Authority with the National Medicines & Therapeutic Committee of Fiji (NMTC) using National Standard Treatment Guidelines (STGs) and Clinical Practice Guidelines (CPGs).



The Fiji EML is based on the World Health Organization's concept of essential medicines, which aims to ensure all medicines listed satisfy the priority health care needs of the Fijian people. The NMTC reviews each medicine for its public health relevance, efficacy, safety and comparative cost-effectiveness.

This edition of the Fiji EML reflects the *National Medicinal Products Policy 2013* concept of rational use of medicines and focuses strongly on the Standard Treatment Guidelines and Clinical Practice Guidelines driving medicines use in Fiji. By using this concept, the aim is to ensure medicines are rationally prescribed adhering to the relevant STGs and CPGs; thereby resulting in accurately predicting medicine usage which will ensure medicine availability at all times in adequate amounts, with assured quality, safety and efficacy and at a price the Fijian community and the Government can afford.

A new streamlined format has been implemented, listing the medicines according to therapeutic areas, thereby making the EML more user-friendly. The alphabetical list of previous editions has been replaced by the index. The index lists all medicines on the EML alphabetically and gives corresponding page numbers in the List which allows readers to quickly locate a medicine in the EML.

In addition, this edition has retained the Vital Medicines and Nursing Station Emergency Kit Lists and includes forms and procedures for: reporting adverse medicine reactions, incidents and medicines issues; applications for amendments to the EML / Therapeutic Guidelines and requests for non-EML medicines.

For any queries regarding the EML please contact the Secretary of the NMTC, *Fiji Pharmaceutical and Biomedical Services (FPBS)*, P.O. Box 106, Suva or by facsimile 3388 003.

The next edition of the EML will be reviewed in 2016.

A handwritten signature in black ink, appearing to read 'Luisa Cikamatana'.

Dr Luisa Cikamatana
Chairperson, National Medicines and Therapeutic Committee
Ministry of Health and Medical Services
Suva, Fiji

Acknowledgements

This edition of the Essential Medicines List has been revised through the efforts of the Fiji Pharmaceutical and Biomedical Services Centre's Essential Medicines Authority with assistance from Crystal Yim, Pharmaceutical Development Officer generously supported by the Australian Volunteers for International Development (AVID) program, an Australian Government initiative. The contents in the report do not necessarily reflect the views of the Australian Government or the Australian Volunteers for International Development program.

Disclaimer

The authors do not warrant the accuracy of the information contained in the Fiji Essential Medicines List (EML) and do not take responsibility for any death, loss, damage or injury caused by using the information in this list.

Whilst every effort has been made to ensure that the Fiji EML is correct and in accordance with current evidence based clinical practices, the dynamic nature of medicines information requires that users exercise in all cases independent professional judgement and understand the individual clinical scenario when referring, prescribing or providing information from the Fiji EML.

Using the Essential Medicines List

2.2 Opioid analgesics		CONTROLLED DRUGS
Codeine	Tablet: 30 mg (phosphate) ³	<ul style="list-style-type: none">• ED Guidelines 2nd ed., 2008• Paediatric CPG 8
Fentanyl	Injection: 50 microgram/mL (2 mL) ¹	<ul style="list-style-type: none">• ED Guidelines 2nd ed., 2008• ICU Guideline for Clin.Mgmt. 1.4, 2010

The medicines are listed alphabetically according to their therapeutic area.

The relevant STGs and CPGs are stated corresponding to each medicine

The number in superscript following the medicine name indicates the level of health facility at which the medicine has been assigned to. For example, fentanyl injection: 50 microgram/mL (2 mL)¹. This means that fentanyl injection is available at Level 1 - Divisional hospital only.

Level 1	Divisional hospital only.
Level 2	Divisional + Specialist hospital only.
Level 3	Divisional + Specialist + Sub divisional hospitals.
Level 4	Divisional + Specialist + Sub divisional hospitals + Health Centres.
Level 5	Divisional + Specialist + Sub divisional hospitals + Health Centres+ Nursing Station.
Level 5a	Divisional + Specialist + Sub divisional hospitals + Health Centres+ Nursing Stations with medical officer's authorisation.
Request Only	Medicines which will only be purchased on request.
Hub	Reproductive Health Clinic & Specialty Clinic for HIV cases

Abbreviations

The following abbreviations have been used in compiling the medicines list:

ART	Antiretroviral Therapy
CPG	Clinical Practice Guideline
CV	Cardiovascular
CWMH	Colonial War Memorial Hospital
ED	Emergency Department
EML	Fiji Essential Medicines List
g	gram
GI	Gastrointestinal
HIV	Human Immunodeficiency Virus
ICU	Intensive Care Unit
IMCI	Integrated Management of Childhood Illness
kg	kilogram
L	litre
mg	milligram
ml	millilitre
NMTC	National Medicines and Therapeutics Committee
POSG	Paediatric Oncology Steering Group
STG	Standard Treatment Guideline
v/v	volume per volume
w/v	weight per volume

Table of Contents

Foreword.....	i
Acknowledgements.....	ii
Disclaimer.....	ii
Using the Essential Medicines List	ii
Abbreviations	iii
Table of Contents.....	iv
1 ANAESTHETICS	1
1.1 General anaesthetics and oxygen.....	1
1.1.1 Inhalational medicines.....	1
1.1.2 Injectable medicines.....	1
1.2 Local anaesthetics	1
1.3 Preoperative medicine and sedation for short-term procedures	1
2 MEDICINES FOR PAIN AND PALLIATIVE CARE	1
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs).....	1
2.2 Opioid analgesics CONTROLLED DRUGS	2
3 ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS	2
4 ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS	3
4.1 Non-specific	3
4.2 Specific.....	3
4.2.1 Anticholinesterase poisoning	3
4.2.2 Ciguatera poisoning.....	3
4.2.3 Iron overdose.....	3
4.2.4 Opioid overdose	3
4.2.5 Paracetamol overdose.....	3
4.2.6 Paraquat poisoning (e.g. Gramaxone).....	3
5 ANTICONVULSANTS / ANTIEPILEPTICS	3
6 ANTI-INFECTIVE MEDICINES.....	4
6.1 Antibacterials.....	4
6.1.1 Beta Lactam medicines.....	4
6.1.2 Aminoglycosides.....	6
6.1.3 Tetracyclines.....	6
6.1.4 Macrolides	7

6.1.5	Quinolones.....	7
6.1.6	Nitroimidazoles.....	7
6.1.7	Glycopeptides.....	8
6.1.8	Carbapenems.....	8
6.1.9	Other Antibacterials	8
6.2	<i>Specific Antibacterial Therapy</i>	9
6.2.1	Antituberculosis medicines and Antileprosy medicines.....	9
6.3	<i>Antifungal medicines</i>	10
6.3.1	Azoles.....	10
6.3.2	Other Antifungal agents	10
6.3.3	Antifungal Vaginal Medicines	10
6.4	<i>Antiviral medicines</i>	10
6.4.1	Antiviral medicines	10
6.4.2	Topical Antiviral medicines.....	10
6.4.3	Antiretroviral Medicines.....	11
6.5	<i>Antiprotozoal medicines</i>	12
6.5.1	Antimalarial medicines	12
6.5.2	Medicines for Toxoplasmosis	12
7	ANTINEOPLASTIC AND IMMUNOSUPPRESSIVES.....	12
7.1	<i>Immunosuppressive medicines</i>	12
7.1.1	Corticosteroids	12
7.2	<i>Antineoplastics</i> <i>CONSULTANT USE ONLY (CYTOTOXIC)</i>	13
7.2.1	Alkylating agents.....	13
7.2.2	Anthracyclines	13
7.2.3	Antimetabolites	14
7.2.4	Platinum compounds.....	14
7.2.5	Taxanes.....	14
7.2.6	Vinca alkaloids	14
7.2.7	Other antineoplastics	15
7.2.8	Anti-oestrogens	15
7.2.9	Gonadotrophin-releasing hormone agonists	15
7.3	<i>Medicines used with antineoplastics</i>	15
8	ANTIPARKINSONISM MEDICINES	16
9	MEDICINES AFFECTING THE BLOOD	16

9.1	<i>Antianaemia medicines</i>	16
9.2	<i>Medicines affecting coagulation</i>	16
9.2.1	Vitamin K Antagonists	16
9.2.2	Heparins.....	16
9.2.3	Antiplatelets	16
9.2.4	Thrombolytics	16
9.2.5	Heparin Antagonist.....	16
9.2.6	Warfarin overdose / rat poisoning	17
10	CARDIOVASCULAR MEDICINES	17
10.1	<i>Antianginal medicines</i>	17
10.1.1	Nitrates	17
10.2	<i>Antiarrhythmic medicines</i>	17
10.3	<i>Antihypertensive medicines</i>	18
10.3.1	Thiazide diuretics.....	18
10.3.2	Aldosterone antagonists and Potassium-sparing diuretics	18
10.3.3	Beta-blockers.....	18
10.3.4	Angiotensin Converting Enzyme (ACE) Inhibitors.....	18
10.3.5	Calcium channel blockers	18
10.3.6	Vasodilators	18
10.3.7	Centrally acting antihypertensives	19
10.4	<i>Medicines in the treatment of pre-eclampsia</i>	19
10.5	<i>Sympathomimetics</i>	19
10.6	<i>Other medicines affecting the vasculature</i>	19
10.7	<i>Medicines used in the treatment of Raynaud's phenomenon</i>	19
10.8	<i>Medicines for Dyslipidaemia</i>	19
10.9	<i>Medicines for congenital heart defects</i>	19
11	DERMATOLOGICAL MEDICINES	20
11.1	<i>Antifungal medicines</i>	20
11.2	<i>Antibacterial medicines</i>	20
11.3	<i>Scabicides</i>	20
11.4	<i>Anaesthetic</i>	20
11.5	<i>Anti-inflammatory and antipruritic medicines</i>	20
11.6	<i>Medicines affecting skin differentiation & proliferation – SKIN CLINIC ONLY</i>	20
11.7	<i>Miscellaneous</i>	20

12	DISINFECTANTS AND ANTISEPTICS.....	20
12.1	<i>Antiseptics</i>	20
12.2	<i>Disinfectants.....</i>	21
13	Urinary Tract Medicines	21
13.1	<i>Diuretics.....</i>	21
13.2	<i>Anticholinergics</i>	21
13.3	<i>Irrigations</i>	21
13.4	<i>Dialysis solution.....</i>	21
14	GASTROINTESTINAL MEDICINES	22
14.1	<i>Antiulcer medicines.....</i>	22
14.1.1	<i>Antacids</i>	22
14.1.2	<i>Histamine (H₂) Receptor Antagonists.....</i>	22
14.1.3	<i>Proton pump inhibitors</i>	22
14.2	<i>Antiemetic medicines.....</i>	22
14.3	<i>Immunosuppressive medicines</i> <i>CONSULTANT USE ONLY.....</i>	23
14.4	<i>Laxatives.....</i>	23
14.5	<i>Medicines used in diarrhoea.....</i>	23
14.5.1	<i>Oral rehydration</i>	23
14.5.2	<i>Supplements for diarrhoea in children.....</i>	23
14.5.3	<i>Antimotility medicines.....</i>	23
14.6	<i>Anti-infective medicines in Diarrhoeal Diseases.....</i>	24
14.6.1	<i>Strongyloidiasis.....</i>	24
14.6.2	<i>Worms (Helminths)</i>	24
14.7	<i>Medicines used in Complications of Liver Disease.....</i>	24
14.7.1	<i>Medicines used in Hepatic Encephalopathy.....</i>	24
15	HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES.....	24
15.1	<i>Diagnostic agent for adrenocortical function.....</i>	24
15.2	<i>Antidiuretic hormone agonist.....</i>	24
15.3	<i>Medicines used in autonomic neuropathy.....</i>	24
15.4	<i>Thyroid hormones and antithyroid medicines.....</i>	24
15.5	<i>Estrogens</i>	24
15.6	<i>Progestogens</i>	24
15.7	<i>Contraceptives.....</i>	25
15.7.1	<i>Oral hormonal contraceptives.....</i>	25

15.7.2	Barrier Contraceptives.....	25
15.7.3	Emergency contraceptive	25
15.7.4	Injectable hormonal contraceptives.....	25
15.7.5	Implantable contraceptives.....	25
15.7.6	Intrauterine Devices	25
16	MEDICINES USED FOR DIABETES.....	25
16.1	<i>Insulins</i> * REFRIGERATE*	25
16.2	<i>Oral Medicines used to Treat Diabetes.....</i>	25
16.3	<i>Medicines for hypoglycaemia.....</i>	26
16.4	<i>Medicines used in diabetic ketoacidosis.....</i>	26
16.5	<i>Medicines used in peripheral neuropathy</i>	26
17	IMMUNOLOGICALS	26
17.1	<i>Diagnostic agents</i>	26
17.2	<i>Sera and immunoglobulins.....</i>	26
17.3	<i>Vaccines.....</i>	27
18	MUSCLE RELAXANTS AND ANTICHOLINESTERASES.....	27
18.1	<i>Muscle Relaxants.....</i>	27
18.2	<i>Anticholinesterases.....</i>	28
19	OPHTHALMOLOGICAL PREPARATIONS.....	28
19.1	<i>Anti-infective medicines.....</i>	28
19.1.1	<i>Antibacterials.....</i>	28
19.1.2	<i>Antivirals.....</i>	28
19.1.3	<i>Antifungals.....</i>	28
19.2	<i>Anti-inflammatory agents</i>	28
19.3	<i>Local anaesthetics and supplementary medicines</i>	28
19.4	<i>Diagnostic agents</i>	28
19.5	<i>Miotics and antiglaucoma medicines.....</i>	29
19.5.1	<i>Beta-blockers.....</i>	29
19.5.2	<i>Carbonic Anhydrase Inhibitors</i>	29
19.5.3	<i>Parasympathetic (Cholinergic) Agonists.....</i>	29
19.5.4	<i>Hyperosmotic Agents</i>	29
19.6	<i>Mydriatics and cycloplegia</i>	29
19.7	<i>Ocular lubricants.....</i>	29
19.8	<i>Vasoconstrictors</i>	29

20	UTEROTONICS AND ANTIUTEROTONICS.....	29
21	MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS	30
21.1	<i>Medicines used in psychotic disorders.....</i>	30
21.1.1	Medicines used in Neuroleptic (Antipsychotic) Malignant Syndrome	31
21.1.2	Medicines to Reduce Extrapyrarnidal effects	31
21.2	<i>Medicines used in mood disorders</i>	31
21.2.1	Medicines used in depressive disorders.....	31
21.2.2	Medicines used in bipolar disorders.....	31
21.3	<i>Medicines used in anxiety disorders.....</i>	32
22	MEDICINES ACTING ON THE RESPIRATORY TRACT.....	32
22.1	<i>Antiasthmatic and medicines for chronic obstructive pulmonary disease</i>	32
22.1.1	Beta ₂ receptor stimulating medicines	32
22.1.2	Anticholinergic bronchodilators	32
22.1.3	Methylxanthines.....	32
22.1.4	Inhaled Corticosteroids	33
22.1.5	Other Antiasthmatic medicines	33
23	SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES	33
23.1	<i>Oral.....</i>	33
23.2	<i>Parenteral.....</i>	33
24	VITAMINS AND MINERALS.....	34
25	SPECIFIC MEDICINES FOR NEONATAL CARE	35
25.1	<i>Medicines administered to the neonate.....</i>	35
26	MEDICINES FOR DISEASES OF JOINTS AND BONES	35
26.1	<i>Medicines used for gout</i>	35
26.2	<i>Medicines used for bones</i>	35
27	DENTAL MEDICINES.....	35
27.1	<i>Ulcers.....</i>	35
27.2	<i>Antifungal.....</i>	35
27.3	<i>Anaesthetic.....</i>	35
28	NUTRITION.....	35
28.1	<i>Enteral Feeding Supplements</i>	36
29	EAR, NOSE AND THROAT MEDICINES	36
29.1	<i>Ear medicines.....</i>	36
29.2	<i>Nasal medicines.....</i>	36

29.2.1	Corticosteroids	36
29.2.2	Decongestants	36
29.3	<i>Throat Medicines</i>	36
30	COMPOUNDING INGREDIENTS	36
31	MISCELLANEOUS	37
	Vital Medicines List	38
	Nursing Station Emergency Kit	40
	Medicines Information References	40
	Summary of Forms and Procedures	41
	ADVERSE MEDICINE REACTION REPORT	43
	INSTRUCTIONS FOR APPLICATION FOR MEDICINE AMENDMENTS TO EXISTING TREATMENT GUIDELINES & ESSENTIAL MEDICINE LIST.....	44
	APPLICATION FOR AMENDMENTS TO EXISTING TREATMENT GUIDELINES FOR THE ESSENTIAL MEDICINE LIST	45
	REQUEST FORM FOR MEDICINE NOT ON THE EML	47
	URGENT REQUEST FOR NON-EML MEDICINE	49
	EMERGENCY PURCHASE PROCEDURE FOR REQUESTED MEDICINES NOT ON THE EML	50
	MEDICINE INCIDENT REPORT FORM	51
	REPORTING MEDICINE / PRODUCT COMPLAINT GUIDELINES	52
	MEDICINE QUALITY COMPLAINT FORM	53
	MEDICINE RECALL PROCEDURE	54
	MEDICINE RECALL PRO FORMA	55
	INDEX	56

1 ANAESTHETICS		
1.1 General anaesthetics and oxygen		
1.1.1 Inhalational medicines		
Isoflurane	Liquid: 500 mL ¹	USE SPECIALISED INHALER SETS
Halothane	Liquid: 250 mL ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010
1.1.2 Injectable medicines		
Ketamine	Injection: 20 mg/mL (5mL) (hydrochloride) ¹	<ul style="list-style-type: none"> Paediatric CPG 8 ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Guidelines 2nd ed., 2008
Thiopentone	Powder for injection: 2.5 g (sodium) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
1.2 Local anaesthetics		
Bupivacaine	Plain injection: 5 mg/mL (4 mL) (hydrochloride) ¹	
Bupivacaine + Adrenaline	Injection: 5 mg/mL bupivacaine hydrochloride + 5 microgram/mL adrenaline (0.5% + 1:200 000) ¹	
Bupivacaine + Dextrose	Spinal heavy injection: 5 mg/mL bupivacaine hydrochloride + 80 mg/mL dextrose (4 mL) ¹	
Lignocaine	Injection: 1% (equivalent to 10 mg/ mL) (20mL) ¹ Injection: 2% (20 mL) ^{5a}	<ul style="list-style-type: none"> Paediatric CPG 8
Lignocaine + Adrenaline	Injection: 2% / 1:200,000 ¹ Injection: 2% / 1:80,000 ⁴	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014
1.3 Preoperative medicine and sedation for short-term procedures		
Atropine	Injection: 600 microgram/mL (sulphate) ^{5a}	
Chloral Hydrate	PAEDIATRIC USE ONLY Oral liquid: 100mg/mL (200mL) ¹	<ul style="list-style-type: none"> Paediatric CPG 8
Diazepam	Injection: 10 mg/2mL ^{5a}	<ul style="list-style-type: none"> Paediatric CPG 8
Lignocaine + Prilocaine (Emla®)	PAEDIATRIC USE ONLY Patch: 25mg lignocaine + 25mg prilocaine ¹	<ul style="list-style-type: none"> Paediatric CPG 8
Midazolam	Injection: 5 mg/mL (2 mL) ¹ PAEDIATRIC USE ONLY Oral solution: 2 mg/mL (200 mL) ¹	<ul style="list-style-type: none"> Paediatric CPG 8 ED Guidelines 2nd ed., 2008 ICU Guideline for Clin.Mgmt. 1.4, 2010
2 MEDICINES FOR PAIN AND PALLIATIVE CARE		
2.1 Non-opioids and non-steroidal anti-inflammatory medicines (NSAIDs)		
Aspirin	Tablet: 300 mg ⁵	<ul style="list-style-type: none"> Paediatric CPG 8 Palliative Care in Paed. Oncology, 2008 CWMH Chemotherapy Protocol Polycythemia vera disorder, 2013 CV Therap. Guidelines 3rd ed., 2015

Ibuprofen	Tablet: 400 mg ⁴	<ul style="list-style-type: none"> • Oral Health CPG 4.1 • Paediatric CPG 8 • Palliative Care in Paed. Oncology, 2008 • CV Therap. Guidelines 3rd ed., 2015
Indomethacin	Capsule: 25 mg ⁴	
Paracetamol	Tablet: 500 mg ⁵ Oral Liquid: 120 mg/5mL (100mL) ⁵ Suppository: 125 mg ³ ; 500 mg ¹	<ul style="list-style-type: none"> • Paediatric CPG 8 • Oral Health CPG 4.1 • Pathology CPG 7.1 • Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 • Resp. Drug Guidelines 1st Ed., 2008 • ED Guidelines 2nd ed., 2008 • ICU Guideline for Clin.Mgmt. 1.4, 2010 • HIV Care and ART Guidelines 2nd ed., 2013 • Palliative Care in Paed. Oncology, 2008

2.2 Opioid analgesics **CONTROLLED DRUGS**

Codeine	Tablet: 30 mg (phosphate) ³	<ul style="list-style-type: none"> • ED Guidelines 2nd ed., 2008 • Paediatric CPG 8
Fentanyl	Injection: 50 microgram/mL (2 mL) ¹	<ul style="list-style-type: none"> • ED Guidelines 2nd ed., 2008 • ICU Guideline for Clin.Mgmt. 1.4, 2010
Methadone	Tablet: 5 mg ¹	<ul style="list-style-type: none"> • Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010 • Palliative Care in Paed. Oncology, 2008
Morphine	Injection: 10 mg/mL (sulphate) ^{5a} Oral liquid: 10 mg/mL (30 mL) (sulphate) ³ Slow release tablet: 10 mg; 30 mg(sulphate) ³	<ul style="list-style-type: none"> • Paediatric CPG 8 • Obstetrics & Gynaecology CPGs Version 1.1, June 2014 • GI Drug Guidelines 1st Ed., 2010 • ED Guidelines 2nd ed., 2008 • ICU Guideline for Clin.Mgmt. 1.4, 2010 • Palliative Care in Paed. Oncology, 2008 • CV Therap. Guidelines 3rd ed., 2015
Pethidine	Injection: 50 mg/mL ^{5a} ; 100 mg/mL ^{5a}	<ul style="list-style-type: none"> • ED Guidelines 2nd ed., 2008

3 ANTIALLERGICS AND MEDICINES USED IN ANAPHYLAXIS

Adrenaline	Injection: 1 mg/mL (tartrate) ⁵ Nebulised Ampoule: 1 mg/ mL (tartrate) ^{5a}	<ul style="list-style-type: none"> • ICU Guideline for Clin.Mgmt. 1.4, 2010 • Pathology CPG 7.1 • Paediatric CPG 8 • Antibiotic Guidelines 3rdEd., 2011 • ED Guidelines 2nd ed., 2008 • CV Therap. Guidelines 3rd ed., 2015
Dexamethasone	Injection: 4 mg/mL (phosphate) ³	<ul style="list-style-type: none"> • Antibiotic Guidelines 3rdEd., 2011 • ED Guidelines 2nd ed., 2008

Hydrocortisone	Powder for Injection: 100mg (sodium succinate) ^{5a}	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 Antibiotic Guidelines 3rd Ed., 2011 CV Therap. Guidelines 3rd ed., 2015
Prednisolone	Tablet: 1 mg ¹ ; 5 mg ⁴ ; 20 mg ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 Antibiotic Guidelines 3rd Ed., 2011
Promethazine	Injection: 25mg/mL (2 mL) (hydrochloride) ⁵ Oral liquid: 5 mg/5 mL (hydrochloride) (100 mL) ³ Tablet: 10 mg (hydrochloride) ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 ICU Guideline for Clin.Mgmt. 1.4, 2010 Antibiotic Guidelines 3rd Ed., 2011 Resp. Drug Guidelines 1st Ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Salbutamol	Respirator Solution for use in nebuliser: 5 mg/mL (30 mL) (sulphate) ⁵	<ul style="list-style-type: none"> Emergency Guidelines Pathology CPG 7.1

4 ANTIDOTES AND OTHER SUBSTANCES USED IN POISONINGS

4.1 Non-specific

Charcoal, Activated	Oral liquid: 50 g/250 mL ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
---------------------	--	---

4.2 Specific

4.2.1 Anticholinesterase poisoning

Pralidoxime	Injection: 25 mg/mL (20mL) ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
-------------	--	---

4.2.2 Ciguatera poisoning

Mannitol	Injection: 20% (500 mL) ^{5a}	<ul style="list-style-type: none"> Emergency Guidelines
----------	--	--

4.2.3 Iron overdose

Desferrioxamine	Injection: 100 mg/mL (5 mL) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
-----------------	---	---

4.2.4 Opioid overdose

Naloxone	Injection: 400 microgram/mL (hydrochloride) ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 Paediatric CPG 8 ICU Guideline for Clin.Mgmt. 1.4, 2010
----------	---	---

4.2.5 Paracetamol overdose

Acetylcysteine	Injection: 2 g/10 mL ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
----------------	--	---

4.2.6 Paraquat poisoning (e.g. Gramaxone)

Fuller's Earth	Granule: 60g (2 packs per kit) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
----------------	--	---

5 ANTICONVULSANTS / ANTIEPILEPTICS

Carbamazepine	Tablet: 200 mg ³	<ul style="list-style-type: none"> Palliative Care in Paed. Oncology, 2008
Diazepam	Injection: 5 mg/mL (2 mL) ^{5a} IMCI PROTOCOL Tablet: 5 mg ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010 Palliative Care in Paed. Oncology, 2008

Ethosuximide	Capsule: 250 mg ²	<ul style="list-style-type: none"> Emergency Guidelines Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Magnesium sulphate	OBS & GYNAE CONSULTANT USE ONLY Injection: 50% (2.5 g/5 mL) ³	<ul style="list-style-type: none"> Obstetrics and Gynaecology Clinical Practice Guidelines Version 1.1, June 2014; Severe pre-eclampsia & Eclampsia
Midazolam	Injection: 5 mg/mL (2 mL) ¹	<ul style="list-style-type: none"> Emergency Guidelines
Phenytoin	Chewable Tablet: 50 mg (sodium) ¹ Tablet: 100 mg (sodium) ⁴ Injection: 50 mg/mL (sodium) (5 mL) ^{5a} Oral liquid: 30 mg/5 mL (500 mL) (sodium) ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 ICU Guideline for Clin.Mgmt. 1.4, 2010 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010 Palliative Care in Paed. Oncology, 2008
Phenobarbitone	Injection: 200 mg/mL (sodium) ¹ Oral liquid: 100 mg/5 mL ¹ Tablet: 30 mg ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 Palliative Care in Paed. Oncology, 2008
Primidone	Tablet: 250 mg ²	ST. GILES USE ONLY

6 ANTI-INFECTIVE MEDICINES

6.1 Antibacterials

6.1.1 Beta Lactam medicines

6.1.1.1 Penicillins

Benzathine Penicillin	Powder for Injection: 2.4 mega International Units ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 CV Therap. Guidelines 3rd ed., 2015
Benzyl penicillin (Penicillin G)	Powder for Injection: 1 mega International Unit ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 ED Guidelines 2nd ed., 2008 GI Drug Guidelines 1st Ed., 2010 ICU Guideline for Clin.Mgmt. 1.4, 2010 Obstetrics & Gynaecology CPGs Version 1.1, June 2014 Resp. Drug Guidelines 1st Ed., 2008
Phenoxymethyl-penicillin (Penicillin V)	Tablet: 250 mg (potassium) ⁴ Powder for Oral Solution: 125 mg/5 mL (potassium) (100 mL) ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 CV Therap. Guidelines 3rd ed., 2015

Procaine Penicillin	Powder for Injection: 3.6 g (4 megaunits) ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Resp. Drug Guidelines 1st Ed., 2008
6.1.1.2 Aminopenicillins		
Ampicillin	Powder for Injection: 500 mg (sodium) ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 GI Drug Guidelines 1st Ed., 2010 ICU Guideline for Clin.Mgmt. 1.4, 2010 Obstetrics & Gynaecology CPGs Version 1.1, June 2014 Paediatric CPG 8
Amoxycillin	Capsule: 250mg ⁴ ; 500 mg ⁴ Powder for Oral liquid: 125 mg/5 mL (100 mL) ⁵	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 ED Guidelines 2nd ed., 2008 GI Drug Guidelines 1st Ed., 2010 Guidelines for the diagnosis management and prevention of Typhoid Fever 11.2 2010 Resp. Drug Guidelines 1st Ed., 2008
6.1.1.3 Anti-Staphylococcal Penicillins		
Cloxacillin	ALTERNATIVE IF FLUCLOXACILLIN UNAVAILABLE Powder for Injection: 500mg (sodium) ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Guideline for Diabetic Foot Sepsis CPG ICU Guideline for Clin.Mgmt. 1.4, 2010 Resp. Drug Guidelines 1st Ed., 2008 Surgery Clinical Practice Guideline 10
Flucloxacillin	Capsule: 250 mg ⁴ ; 500 mg (sodium) ⁴ Injection: 500 mg (sodium) ³ Powder for Oral Liquid: 125 mg/5 mL (sodium) (100 mL) ⁵ IMCI PROTOCOL	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Diabetes Mgmt. Guidelines 3rd Ed. 2012 HIV Care and ART Guidelines 2nd ed., 2013 Resp. Drug Guidelines 1st Ed., 2008
6.1.1.4 Anti-Pseudomonal Penicillins		
Piperacillin + Tazobactam	RESTRICTED ANTIMICROBIAL* Powder for Injection: 4 g piperacillin + 500 mg tazobactam ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Resp. Drug Guidelines 1st Ed., 2008 ICU Guideline for Clin.Mgmt. 1.4, 2010 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008
6.1.1.5 β Lactam and β Lactamase inhibitor Combinations		
Amoxycillin + Clavulanic Acid	Tablet: 500mg Amoxycillin (hydrate) + 125mg Clavulanate (Potassium) ¹ (3,4 & Hub STI cases only)	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Surgery Clinical Practice Guideline 10 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 GI Drug Guidelines 1st Ed., 2010 HIV Care ART Guidelines 2nd ed., 2013

6.1.1.6 Cephalosporins		
First Generation		
Cephalothin	RESTRICTED ANTIMICROBIAL* Powder for Injection: 1 g (sodium)¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Second Generation		
Cefaclor	Modified release tablet: 375 mg (anhydrous)¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Resp. Drug Guidelines 1st Ed., 2008
Third Generation		
Ceftriaxone	RESTRICTED ANTIMICROBIAL* Powder for Injection: 250 mg¹; 1 g (sodium)¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 ED Guidelines 2nd ed., 2008 GI Drug Guidelines 1st Ed., 2010 Guideline for Diabetic Foot Sepsis CPG Guidelines for the diagnosis management and prevention of Typhoid Fever 11.2 2010 ICU Guideline for Clin.Mgmt. 1.4, 2010 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008 Paediatric CPG 8 Resp. Drug Guidelines 1st Ed., 2008 Surgery Clinical Practice Guideline 10
Cefotaxime	RESTRICTED ANTIMICROBIAL* Powder for Injection: 500 mg¹	
6.1.2 Aminoglycosides		
Gentamicin	Injection: 40 mg/mL (2 mL)^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 GI Drug Guidelines 1st Ed., 2010 Guideline for Diabetic Foot Sepsis CPG ICU Guideline for Clin.Mgmt. 1.4, 2010 Obstetrics & Gynaecology CPGs Version 1.1, June 2014 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008 Resp. Drug Guidelines 1st Ed., 2008 Surgery Clinical Practice Guideline 10
6.1.3 Tetracyclines		
Doxycycline	Capsule: 100 mg (hydrochloride)^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Mgmt. Guidelines for STIs 2nd Ed. 11.3 GI Drug Guidelines 1st Ed., 2010 Oral Health CPG 4.1 Resp. Drug Guidelines 1st Ed., 2008

6.1.4 Macrolides		
Azithromycin	<p>FOR STI CASES ONLY</p> <p>Tablet: 500 mg^{Hub}</p>	<ul style="list-style-type: none"> • Antibiotic Guidelines 3rd Ed., 2011 • Guidelines for the diagnosis management and prevention of Typhoid Fever 11.2 2010 • HIV Care & ART Guidelines 2nd ed., 2013 • Oral Health CPG 4.1
Erythromycin	<p>Tablet: 250 mg⁴</p> <p>Powder for Oral Liquid: 125 mg/5 mL (100 mL) (estolate as base)³</p> <p>RESTRICTED ANTIMICROBIAL*</p> <p>Powder for Injection: 1 g (lactobionate)¹</p>	<ul style="list-style-type: none"> • Antibiotic Guidelines 3rd Ed., 2011 • Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 • CV Therap. Guidelines 3rd ed., 2015 • ED Guidelines 2nd ed., 2008 • GI Drug Guidelines 1st Ed., 2010 • Guideline for Diabetic Foot Sepsis CPG • HIV Care and ART Guidelines 2nd ed., 2013 • ICU Guideline for Clin.Mgmt. 1.4, 2010 • Resp. Drug Guidelines 1st Ed., 2008
6.1.5 Quinolones		
Ciprofloxacin	<p>RESTRICTED ANTIMICROBIAL*</p> <p>Tablet: 500 mg (hydrochloride)¹</p> <p>Injection: 2 mg/mL (50 mL) (lactate)¹</p>	<ul style="list-style-type: none"> • Antibiotic Guidelines 3rd Ed., 2011 • GI Drug Guidelines 1st Ed., 2010 • Guidelines for the diagnosis management and prevention of Typhoid Fever 11.2 2010 • ICU Guideline for Clin.Mgmt. 1.4, 2010 • Paediatric CPG 8
6.1.6 Nitroimidazoles		
Metronidazole	<p>Tablet: 200 mg⁴</p> <p>RESTRICTED ANTIMICROBIAL*</p> <p>Injection: 5 mg/mL (100 mL)¹</p> <p>Suppository: 500 mg¹</p>	<ul style="list-style-type: none"> • Antibiotic Guidelines 3rd Ed., 2011 • Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 • Diabetes Mgmt. Guidelines 3rd Ed. 2012 • ED Guidelines 2nd ed., 2008 • GI Drug Guidelines 1st Ed., 2010 • HIV Care and ART Guidelines 2nd ed., 2013 • ICU Guideline for Clin.Mgmt. 1.4, 2010 • Obstetrics & Gynaecology CPGs Version 1.1, June 2014 • Oral Health CPG 4.1 • Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008 • Resp. Drug Guidelines 1st Ed., 2008 • Surgery Clinical Practice Guideline 10

6.1.7 Glycopeptides		
Vancomycin	RESTRICTED ANTIMICROBIAL* Powder for Injection: 500 mg (hydrochloride) ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011. GI Drug Guidelines 1st Ed., 2010 ICU Guideline for Clin.Mgmt. 1.4, 2010 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008
6.1.8 Carbapenems		
Meropenem	RESTRICTED ANTIMICROBIAL* Powder for Injection: 500mg ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008
6.1.9 Other Antibacterials		
Amikacin	RESTRICTED ANTIMICROBIAL* Injection: 250 mg (250 000 International Units) ^{1, Request only}	<ul style="list-style-type: none"> Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008
Chloramphenicol	Capsule: 250 mg ⁴ Oral Liquid: 125 mg/5 mL ⁴ Powder for Injection: 1 g ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 ED Guidelines 2nd ed., 2008 GI Drug Guidelines 1st Ed., 2010 Guidelines for the diagnosis management and prevention of Typhoid Fever 11.2 2010 ICU Guideline for Clin.Mgmt. 1.4, 2010 ICU Guideline for Clin.Mgmt. 1.4, 2010 Resp. Drug Guidelines 1st Ed., 2008
Colistin	Powder for injection: 150 mg (4 500 000 International Units) ^{1 - Request only}	RESTRICTED ANTIMICROBIAL*
Cotrimoxazole (Sulfamethoxazole +Trimethoprim)	Oral Liquid: 240 mg/5 mL ⁵ (5mL contains: Sulfamethoxazole 200 mg and Trimethoprim 40 mg) Tablet: 400 mg sulfamethoxazole + 80 mg trimethoprim ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 CWMH: Lymphoma Protocols 2013 GI Drug Guidelines 1st Ed., 2010 Guidelines for the diagnosis management and prevention of Typhoid Fever 11.2 2010 HIV Care ART Guidelines 2nd ed., 2013 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008 Pneumocystis jiroveci Pneumonia Resp. Drug Guidelines 1st Ed., 2008
Nitrofurantoin	Tablet: 100 mg ³	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Rifampicin	Capsule: 150 mg ² ; 300 mg ² Oral Liquid: 100 mg/5 mL (60 mL) ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 ED Guidelines 2nd ed., 2008 ICU Guideline for Clin.Mgmt. 1.4, 2010 Paediatric CPG 8 Resp. Drug Guidelines 1st Ed., 2008

Silver Nitrate	Stick⁴	
Silver Sulphadiazine	Cream: 1% w/w (500 g) ³	
Trimethoprim	Oral Liquid: 50 mg/5 mL (100 mL) ⁵ Tablet: 300 mg ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Complementary Antibacterial List		
Probenacid	Tablet: 500 mg ⁴	<ul style="list-style-type: none"> Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 Antibiotic Guidelines 3rd Ed., 2011
6.2 Specific Antibacterial Therapy		
6.2.1 Antituberculosis medicines and Antileprosy medicines		
Dapsone	TWOMEY HOSPITAL USE ONLY Tablet: 50 mg; 100 mg ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Ethambutol	Tablet: 400 mg (Hydrochloride) ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Tuberculosis Guideline 2011
Isoniazid	Tablet: 100 mg ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Tuberculosis Guideline 2011
Pyrazinamide	Tablet: 500 mg ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Tuberculosis Guideline 2011
Rifampicin	Capsule: 150 mg; 300 mg ² Oral Liquid: 100 mg/50 mL (60 mL) ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Tuberculosis Guideline 2011
Rifampicin + Isoniazid	Capsule: 150 mg Rifampicin + 100 mg Isoniazid ² Capsule: 300 mg Rifampicin + 150 mg Isoniazid ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Tuberculosis Guideline 2011
Streptomycin	Injection: 1 g ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Tuberculosis Guideline 2011
Stop TB Kit Category I & III	Intensive phase fixed dose combination tablet: Rifampicin 150 mg + Isoniazid 75 mg + Pyrazinamide 400 mg + Ethambutol 275 mg Continuation phase fixed dose combination tablet: Rifampicin 150 mg + Isoniazid 75 mg ²	
Stop TB Kit Category II	Intensive phase fixed dose combination tablet: Rifampicin 150 mg + Isoniazid 75 mg + Pyrazinamide 400 mg + Ethambutol 275 mg Intensive phase Injection: Streptomycin 1 g Continuation phase fixed dose combination tablet: Rifampicin 150 mg + Isoniazid 75 mg + Ethambutol 275 mg ²	

6.3 Antifungal medicines		
6.3.1 Azoles		
Fluconazole	RESTRICTED ANTIFUNGAL* Capsule: 200 mg ^{Hub/1} Injection: 2 mg/mL (100 mL) ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 GI Drug Guidelines 1st Ed., 2010 HIV Care and ART Guidelines 2nd ed., 2013 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008
Ketoconazole	FOR DERMATOLOGY CLINIC ONLY Tablet: 200 mg ²	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010 HIV Care and ART Guidelines 2nd ed., 2013
6.3.2 Other Antifungal agents		
Amphotericin B	RESTRICTED ANTIFUNGAL* Lyophilized powder for injection: 50mg ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 HIV Care and ART Guidelines 2nd ed., 2013 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008
Griseofulvin	Tablet: 125 mg ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 HIV Care and ART Guidelines 2nd ed., 2013
Terbinafine	Tablet: 250 mg ⁴	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
6.3.3 Antifungal Vaginal Medicines		
Econazole	Vaginal pessary: 150 mg ⁴	<ul style="list-style-type: none"> Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 Antibiotic Guidelines 3rd Ed., 2011
Miconazole	FOR GYNAE CLINIC ONLY Vaginal cream: 2% (nitrate) ¹	<ul style="list-style-type: none"> Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3
6.4 Antiviral medicines		
6.4.1 Antiviral medicines		
Aciclovir	RESTRICTED ANTIVIRAL* Injection: 250 mg (sodium) ¹ Tablet: 200 mg ^{1,Hub}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3 CWMH Chemotherapy Protocols: Lymphoma Protocols, 2013 HIV Care and ART Guidelines 2nd ed., 2013 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008 Palliative Care in Paed. Oncology, 2008
6.4.2 Topical Antiviral medicines		
Podophyllotoxin	Tincture: 0.5% ^{Request only Hub}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011

6.4.3 Antiretroviral Medicines		
6.4.3.1 Nucleoside / Nucleotide reverse transcriptase inhibitors (NRTIs)		
Abacavir (ABC)	Tablet: 300 mg ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Didanosine (ddI)	Capsule: 200 mg; 400 mg ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Lamivudine (3TC)	Oral Liquid: 10 mg/mL (240 mL) ^{Hub/1} Tablet: 150 mg ^{Hub/1}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 HIV Care and ART Guidelines 2nd ed., 2013
Stavudine (d4T)	Capsule: 30 mg ^{Hub/1} Oral Liquid: 1 mg/mL ^{Hub/1}	
Tenofovir (TDF)	Tablet: 300 mg ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Zidovudine (AZT)	Oral Liquid: 10 mg/mL (240 mL) ^{Hub/1} Tablet: 300 mg ^{Hub}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 HIV Care and ART Guidelines 2nd ed., 2013
6.4.3.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)		
Efavirenz (EFV)	Tablet: 600 mg ^{Hub/1} Oral liquid: 30 mg/mL (180 mL) ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Nevirapine (NVP)	Oral Liquid: 10 mg/mL (240 mL) ^{Hub/1} Tablet: 200 mg ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
6.4.3.3 Protease inhibitors (PIs)		
Lopinavir + Ritonavir (LPV/r)	Oral liquid: Lopinavir 80 mg/mL + Ritonavir 20 mg/mL (60 mL) ^{Hub/1} Tablet: 200 mg lopinavir + 50 mg ritonavir ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
6.4.3.4 FIXED DOSE COMBINATIONS		
Lamivudine + Stavudine (3TC + d4T)	Tablet: Lamivudine 150 mg + Stavudine 30 mg ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Lamivudine + Stavudine + Nevirapine (3TC + d4T + NVP)	Tablet: Lamivudine 150 mg + Stavudine 30 mg + Nevirapine 200 mg ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Lamivudine + Tenofovir (TDF + 3TC)	Tablet: Lamivudine 300 mg + Tenofovir 300 mg ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Lamivudine + Tenofovir + Efavirenz (TDF + 3TC + EFV)	Tablet: Lamivudine 300 mg + Tenofovir 300 mg + Efavirenz 600 mg ^{Hub}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Lamivudine + Zidovudine (3TC + AZT)	Dispersible tablet: Lamivudine 30 mg + Zidovudine 60 mg ^{Hub/1} Tablet: Lamivudine 150 mg + Zidovudine 300 mg ^{1/Hub}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013

Lamivudine + Zidovudine + Efavirenz (3TC + AZT + EFV)	Day Pack: (Lamivudine 150 mg + Zidovudine 300 mg combination x 2 tablets) + Efavirenz 600 mg (1 x tablet) ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Lamivudine + Zidovudine + Nevirapine (3TC + AZT + NVP)	Dispersible tablet: Lamivudine 30 mg + Zidovudine 60 mg + Nevirapine 50 mg ^{Hub/1} Tablet: Lamivudine 150 mg + Zidovudine 300 mg + Nevirapine 200 mg ^{Hub/1}	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013

6.5 Antiprotozoal medicines

6.5.1 Antimalarial medicines

6.5.1.1 For curative treatment

Doxycycline	Capsule: 100 mg (Hydrochloride) ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011
Hydroxychloroquine	Tablet: 200 mg ^{2,Request only}	
Primaquine	Tablet: 7.5 mg ^{1,Request only}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011
Quinine	Injection: 60mg/mL (10 mL) (dihydrochloride) ¹ Tablet: 200mg (sulphate) ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011

6.5.1.2 For prophylaxis

Doxycycline	Capsule: 100 mg (hydrochloride) ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011
-------------	--	---

6.5.2 Medicines for Toxoplasmosis

Cotrimoxazole (Sulfamethoxazole + Trimethoprim)	Oral Liquid: 240 mg/5 mL ^{5a} (5mL contains: Sulfamethoxazole 200mg and Trimethoprim 40mg) Tablet: 400mg sulfamethoxazole + 80mg trimethoprim ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011
Dapsone	Tablet: 50 mg; 100 mg ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011

7 ANTINEOPLASTIC AND IMMUNOSUPPRESSIVES

7.1 Immunosuppressive medicines

7.1.1 Corticosteroids

Dexamethasone	Injection: 4 mg/mL (phosphate) ³ Tablet: 500 microgram ¹ ; 2 mg ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011 CV Therap. Guidelines 3rd ed., 2015 CWMH Chemotherapy Protocol: Testicular, Breast Cancer, Gynaecological and Haematology Protocols 2013 ED Guidelines 2nd ed., 2008 Paediatric CPG 8
---------------	---	---

Hydrocortisone	Powder for Injection: 100 mg (sodium succinate) ⁴ Tablet: 20 mg ¹	<ul style="list-style-type: none"> • ICU Guideline for Clin.Mgmt. 1.4, 2010 • Obstetrics & Gynaecology CPGs Version 1.1, June 2014 • Resp. Drug Guidelines 1st Ed., 2008 • ED Guidelines 2nd ed., 2008 • CWMH Chemotherapy Protocol modified CMF: Breast Cancer, 2013 • ED Asthma Care Pathway 2014 • GI Drug Guidelines 1st Ed., 2010
Methylprednisolone	Injection: 1 g (sodium succinate) ¹	CONSULTANT USE ONLY
Prednisolone	Tablet: 1mg ¹ ; 5mg ⁴ ; 20mg ¹ (acetate)	<ul style="list-style-type: none"> • Obstetrics & Gynaecology CPGs Version 1.1, June 2014 • ED Guidelines 2nd ed., 2008 • CWMH Chemotherapy Haematology Protocols • CV Therap. Guidelines 3rd ed., 2015 • Tuberculosis Guideline 2011 • Paediatric CPG 8 • ED Asthma Care Pathway 2014 • Resp. Drug Guidelines 1st Ed., 2008 • GI Drug Guidelines 1st Ed., 2010 • HIV Care and ART Guidelines 2nd ed., 2013
Triamcinolone	Injection: 10 mg/mL ²	
7.2 Antineoplastics CONSULTANT USE ONLY (CYTOTOXIC)		
7.2.1 Alkylating agents		
Chlorambucil	Tablet: 5 mg ¹	<ul style="list-style-type: none"> • CWMH Chemotherapy Protocol Chlorambucil: Chronic Lymphocytic Leukaemia, 2013
Cyclophosphamide	Powder for Injection: 200 mg ¹ ; 500 mg ¹ ; 1 g ¹ Tablet: 50 mg ¹	<ul style="list-style-type: none"> • CWMH Chemotherapy Protocols: Breast, Haematology, Gynaecological Protocols 2013
Dacarbazine	Powder for Injection: 200 mg ¹	<ul style="list-style-type: none"> • POSG Pacific Island Workstream – Hodgkin's Lymphoma (Hodgkin's Disease, HD) PI HD-1 Protocol • CWMH Chemotherapy Protocol ABVD: Hodgkin's Lymphoma, 2013
Melphalan	Tablets: 5 mg ¹	<ul style="list-style-type: none"> • CWMH Chemotherapy Protocol M&P: Multiple Myeloma, 2013
7.2.2 Anthracyclines		
Daunorubicin	Injection: 2 mg/mL (10 mL) (hydrochloride) ¹	<ul style="list-style-type: none"> • Paediatric Oncology Steering Group – Acute Promyelocytic Leukaemia PI-APML 1 Protocol, 2008

Doxorubicin (Adriamycin)	Injection: 2 mg/mL (25 mL) ¹	<ul style="list-style-type: none"> Paediatric Oncology Steering Group – Wilms Tumour PI-WT1 Protocol, 2008 National Child Cancer Network Pacific Island Workstream – Osteosarcoma Guideline PI-OS 1.0, 2012 CWMH Chemotherapy Protocols for Lymphomas, 2013
7.2.3 Antimetabolites		
Fluorouracil (5-Fluorouracil)	Injection: 50 mg/mL (sodium) (10 mL) ¹	<ul style="list-style-type: none"> CWMH Chemotherapy Protocol modified CMF: Breast Cancer, 2013 CWMH Chemotherapy Protocol MAYO clinic: Colorectal Cancer, 2013
Hydroxyurea	Capsule: 500 mg ¹	<ul style="list-style-type: none"> CWMH Chemotherapy Protocol Chronic Myeloid Leukaemia, 2013 CWMH Chemotherapy Protocol Hydroxyurea: Essential thrombocythemia (myeloproliferative disorder), 2013 CWMH Chemotherapy Protocol Hydroxyurea: Polycythemiavera (myeloproliferative disorder), 2013
6 – Mercaptopurine	Tablet: 50 mg ¹	<ul style="list-style-type: none"> Paediatric Oncology Steering Group – Acute Promyelocytic Leukaemia PI-APML 1 Protocol, 2008
Methotrexate	Injection: 25 mg/mL (sodium) (2 mL) ¹ Tablet: 2.5 mg (sodium) ¹	<ul style="list-style-type: none"> CWMH Chemotherapy Protocols: Breast, Paediatric Haematology, Gynaecological Protocols 2013 modified CMF: Breast Cancer, 2013
7.2.4 Platinum compounds		
Carboplatin	Injection: 10 mg/mL ¹	<ul style="list-style-type: none"> National Child Cancer Network Pacific Island Workstream – Osteosarcoma Guideline PI-OS 1.0, 2012 POSG Pacific Island Workstream – Germ Cell Tumours PI GC 1 Protocol, 2008
7.2.5 Taxanes		
Paclitaxel	Injection: 100 mg (16.7 mL) ^{Request Only}	<ul style="list-style-type: none"> CWMH Chemotherapy Protocol: Ovarian Cancer (advanced), 2013
7.2.6 Vinca alkaloids		
Vinblastine	Injection: 1 mg/mL (10 mL) (sulphate) ¹	<ul style="list-style-type: none"> POSG Pacific Island Workstream – Hodgkin's Lymphoma (Hodgkin's Disease, HD) PI HD-1 Protocol CWMH Chemotherapy Protocol ABVD: Hodgkin's Lymphoma, 2013 CWM Chemotherapy Protocol: Ovarian germ cell tumour (alternative), 2013

Vincristine	Injection: 1 mg/mL (sulphate) ¹	<ul style="list-style-type: none"> Paediatric Oncology Steering Group – Wilms Tumour PI-WT1 Protocol, 2008 CWMH Chemotherapy Protocol Hodgkin's and Non-Hodgkin's Lymphoma, 2013 CWMH Chemotherapy Protocol EMA-CO: Gestational trophoblastic neoplasia (high risk), 2013
7.2.7 Other antineoplastics		
Actinomycin D (Dactinomycin)	Powder for Injection: 500 micrograms ¹	<ul style="list-style-type: none"> Paediatric Oncology Steering Group – Wilms Tumour PI-WT1 Protocol, 2008 CWMH Chemotherapy Protocols: Gestational trophoblastic neoplasia Protocols, 2013
Cytarabine (Arabinocide C)	Injection: 100 mg/5mL ¹	
Bleomycin	Powder for Injection: 15 000 International Units ¹	<ul style="list-style-type: none"> CWMH Chemotherapy Protocol: Testicular, Haematology, Gynaecology protocols, 2013
Colaspase (L-Asparaginase)	Powder for Injection: 10 000 International Units ¹	
Procarbazine	Capsule: 50 mg ¹	<ul style="list-style-type: none"> CWMH Chemotherapy Protocol C-MOPP: Hodgkin's Lymphoma, 2013
7.2.8 Anti-oestrogens		
Tamoxifen	CONSULTANT USE ONLY Tablet: 20 mg (citrate) ¹	<ul style="list-style-type: none"> CWMH Chemotherapy Protocol modified CMF: Breast Cancer, 2013
7.2.9 Gonadotrophin-releasing hormone agonists		
Goserelin	Implant: 3.6 mg (acetate) ^{Special request}	UROLOGIST USE ONLY
7.3 Medicines used with antineoplastics		
Calcium Folate (Calcium Leucovorin, Folinic Acid)	CONSULTANT USE ONLY Injection: 10 mg/mL (10 mL) ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 CWMH Chemotherapy Protocol MAYO clinic: Colorectal Cancer, 2013 CWMH Chemotherapy Protocols: Gestational trophoblastic neoplasia protocols, 2013
Mannitol	Injection: 20% (500 mL) ⁵	<ul style="list-style-type: none"> CWMH Chemotherapy Protocol: Ovarian Cancer (advanced), 2013 CWMH Chemotherapy Protocol: Ovarian Cancer, 2013
Methylene Blue	Injection: 1% ¹	<ul style="list-style-type: none"> National Child Cancer Network Pacific Island Workstream – Osteosarcoma Guideline PI-OS 1.0, 2012

8 ANTIPARKINSONISM MEDICINES

Levodopa + Benserazide	Tablet: Levodopa 100 mg + Benserazide 25 mg ² Tablet: Levodopa 200 mg + Benserazide 50 mg ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness Disorders 2010
------------------------	--	---

9 MEDICINES AFFECTING THE BLOOD

9.1 Antianaemia medicines

Ferrous Fumarate	Oral liquid: 200 mg/5 mL (100 mL) ⁵ IMCI	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Ferrous Sulphate	Tablet: 200 mg ⁵	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 GI Drug Guidelines 1st Ed., 2010
Folic Acid	Tablet: 5 mg ⁵	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 GI Drug Guidelines 1st Ed., 2010
Iron Dextran	Injection: 50 mg/mL (2 mL) ⁴	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Vitamin B ₁₂ (Hydroxocobalamin)	Injection: 1 mg/mL ⁴	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010

9.2 Medicines affecting coagulation

9.2.1 Vitamin K Antagonists

Warfarin	Tablet: 1 mg ¹ ; 3 mg ¹ ; 5 mg (sodium) ¹ (MAREVAN® BRAND)	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 CV Therap. Guidelines 3rd ed., 2015
----------	--	---

9.2.2 Heparins

Heparin	Injection: 5 000 units/mL (5 mL) (sodium) ¹	<ul style="list-style-type: none"> Guideline for Perioperative Prophylaxis of VTE in General & Orthopaedic Surgery 2010 ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Guidelines 2nd ed., 2008 Obstetrics & Gynaecology CPGs Version 1.1, June 2014 CV Therap. Guidelines 3rd ed., 2015
---------	---	--

9.2.3 Antiplatelets

Aspirin	Tablet: 100 mg ⁵	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012 ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
---------	------------------------------------	--

9.2.4 Thrombolytics

Streptokinase	CCU CONSULTANT USE ONLY Powder for injection: 1.5 million units ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
---------------	---	--

9.2.5 Heparin Antagonist

Protamine Sulphate	Injection: 10 mg/mL (5 mL) ¹	<ul style="list-style-type: none"> Guideline for Perioperative Prophylaxis of VTE in General & Orthopaedic Surgery 2010 CV Therap. Guidelines 3rd ed., 2015
--------------------	--	---

9.2.6 Warfarin overdose / rat poisoning		
Vitamin K (Phytomenadione)	Injection: 1 mg/mL ³ ; 10 mg/mL ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
10 CARDIOVASCULAR MEDICINES		
10.1 Antianginal medicines		
10.1.1 Nitrates		
Glyceryl trinitrate	Sublingual Tablet: 600microgram ⁵	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Isosorbide dinitrate	Tablet: 10 mg ⁴ CCU CONSULTANT USE ONLY USE NON-PVC ADMINISTRATION SETS Injection: 1 mg/mL (50mL) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
10.2 Antiarrhythmic medicines		
Adenosine	Injection: 6 mg/2 mL ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Adrenaline	Injection: 1 mg/mL (tartrate) ^{5a}	<ul style="list-style-type: none"> CV Therap. Guidelines 3rd ed., 2015
Atenolol	Tablet: 50 mg ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Atropine	Injection: 600 microgram/mL (sulphate) ^{5a}	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Amiodarone	Tablet: 100 mg ¹ Injection: 150 mg/3 mL (hydrochloride) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Digoxin	Injection: 25 micrograms/mL (2 mL) ^{5a} Oral liquid: 50 micrograms/mL ⁴ Tablet: 62.5 microgram (PG) ⁴ ; 250 microgram ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Dopamine	Injection: 40 mg/mL (hydrochloride) (5 mL) ³	<ul style="list-style-type: none"> CV Therap. Guidelines 3rd ed., 2015
Isoprenaline	Injection: 1 mg/mL (2 mL) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Lignocaine	Injection: 1% ¹ (10 mL) ¹ ; 2% (20 mL) ⁵	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015

Magnesium sulphate	Injection: 50% (2.5 g/5 mL) ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Propranolol	Injection: 1 mg/mL (hydrochloride) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Verapamil	Injection: 2.5 mg/mL (2 mL) (hydrochloride) ³ Tablet: 40 mg (hydrochloride) ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
10.3 Antihypertensive medicines		
10.3.1 Thiazide diuretics		
Hydrochlorothiazide	Tablet: 25 mg ⁴	<ul style="list-style-type: none"> CV Therap. Guidelines 3rd ed., 2015
10.3.2 Aldosterone antagonists and Potassium-sparing diuretics		
Spironolactone	Tablet: 25 mg ³	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010 CV Therap. Guidelines 3rd ed., 2015
10.3.3 Beta-blockers		
Atenolol	Tablet: 50 mg ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Labetalol	CONSULTANT USE ONLY Injection: 5 mg/mL (20 mL) (hydrochloride) ¹	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
Propranolol	Injection: 1 mg/mL (hydrochloride) ¹ Tablet: 10 mg ⁴ ; 40 mg (hydrochloride) ⁴	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010 ED Guidelines 2nd ed., 2008 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
10.3.4 Angiotensin Converting Enzyme (ACE) Inhibitors		
Enalapril	Tablet: 5 mg ⁴ ; 10 mg (maleate) ⁴	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012 CV Therap. Guidelines 3rd ed., 2015
10.3.5 Calcium channel blockers		
Amlodipine	Tablet: 5 mg ⁴	<ul style="list-style-type: none"> CV Therap. Guidelines 3rd ed., 2015
Nifedipine	Capsule: 10 mg ⁴	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015
10.3.6 Vasodilators		
Hydralazine	Injection: 20 mg/mL ^{5a} Tablet: 25 mg ⁴	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 ED Guidelines 2nd ed., 2008 CV Therap. Guidelines 3rd ed., 2015

10.3.7 Centrally acting antihypertensives		
Methyldopa	Tablet: 250 mg ⁴	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 CV Therap. Guidelines 3rd ed., 2015
10.4 Medicines in the treatment of pre-eclampsia		
Magnesium sulphate	Injection: 50% (2.5 g/5 mL) ³	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 CV Therap. Guidelines 3rd ed., 2015
10.5 Sympathomimetics		
Adrenaline	Injection: 1 mg/mL (tartrate) ^{5a}	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 Paediatric CPG 8 ED Guidelines 2nd ed., 2008
Dobutamine	Injection: 12.5 mg/mL (20 mL) (hydrochloride) ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 Pathology CPG 7.1 Paediatric CPG 8 ED Guidelines 2nd ed., 2008
Dopamine	Injection: 40 mg/mL (Hydrochloride) (5 mL) ³	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Guidelines 2nd ed., 2008 Paediatric CPG 8 Pathology CPG 7.1
Ephedrine	Injection: 30 mg/mL ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010
Noradrenaline	Injection: 1 mg/mL ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 Paediatric CPG 8 CV Therap. Guidelines 3rd ed., 2015
10.6 Other medicines affecting the vasculature		
Salbutamol	CONSULTANT USE ONLY Injection: 500 microgram/mL (sulphate) ³	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010
10.7 Medicines used in the treatment of Raynaud's phenomenon		
Amlodipine	Tablet: 5 mg ⁴	<ul style="list-style-type: none"> CV Therap. Guidelines 3rd ed., 2015
Glyceryl trinitrate	Ointment: 2% ¹	<ul style="list-style-type: none"> CV Therap. Guidelines 3rd ed., 2015
10.8 Medicines for Dyslipidaemia		
Simvastatin	CONSULTANT USE ONLY Tablet: 20 mg ¹	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012 CV Therap. Guidelines 3rd ed., 2015
10.9 Medicines for congenital heart defects		
Alprostadil (Prostaglandin E1)	Injection: 500 mcg/mL (5mL) ^{special request,1}	PAEDIATRIC USE ONLY

11 DERMATOLOGICAL MEDICINES		
11.1 Antifungal medicines		
Miconazole	Cream: 2% ⁴	
11.2 Antibacterial medicines		
Neomycin	Ointment: 1% ⁴	
11.3 Scabicides		
Benzyl benzoate	Lotion: 25% (200 mL) ⁴	
Permethrin	Cream: 5% (15 g) ⁴	<ul style="list-style-type: none"> Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3
11.4 Anaesthetic		
Lignocaine	Topical spray: 10% (200 mL) ¹ Topical solution: 4% (200 mL) ¹	
11.5 Anti-inflammatory and antipruritic medicines		
Betamethasone	Cream: 0.1% (valerate) ⁴ SKIN CLINIC ONLY Scalp Lotion: 0.1% ¹	
Clobetasol	Ointment: 0.05% (propionate) ²	
Hydrocortisone	Cream: 1% ⁵	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Hammamelis (Witch Hazel)	Ointment: 30 g ⁴	
Triamcinolone	Cream: 0.02% (100 g) (acetanide) ²	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
11.6 Medicines affecting skin differentiation & proliferation – SKIN CLINIC ONLY		
Coal Tar	Ointment: (100 g) ²	
Psoriasis	Ointment: 100 g ²	
11.7 Miscellaneous		
Magnesium sulphate	Paste: 50 g ⁵	
Plastic spray	Spray ¹	
12 DISINFECTANTS AND ANTISEPTICS		
12.1 Antiseptics		
Acetic Acid	Solution: 6% (500 mL) ³	SURGICAL AND GYNAE USE ONLY

Cetrimide + Chlorhexidine	Aqueous Cream: 15% Cetrimide + 1.5% chlorhexidine (50 g) ⁵ Solution: Cetrimide 15% + Chlorhexidine gluconate 1.5% (500 mL) ⁵	
Chlorhexidine	Obstetric cream: 1% w/w (500 g) (Gluconate) ⁵ Solution: 20% (4 L) ¹ FOR EXTERNAL USE ONLY	
Hydrogen Peroxide	Solution: 6% (200 mL) ¹	FOR SURGICAL USE ONLY
Povidone Iodine Aqueous	Solution: 10% (500 mL) ³	<ul style="list-style-type: none"> HIV Care and ART Guidelines 2nd ed., 2013
Povidone Iodine Alcoholic	Solution: 10% (500 mL) ³	FOR SURGICAL USE ONLY
Povidone Iodine Scrub	Solution: 7.5% (500 mL) ³	FOR SURGICAL USE ONLY
12.2 Disinfectants		
Alcohol (SVR)	Solution: 96% (1 L) ¹	
Glutaraldehyde	Solution: 2% (stabilised) ¹	
Methylated Sprits	Solution: 70% ⁵	
Sodium hypochlorite	Solution: 1% (1 L and 5 L) ⁵	HOSPITAL GRADE
13 Urinary Tract Medicines		
13.1 Diuretics		
Furosemide	Injection: 10 mg/mL (2 mL) ^{5a} Tablet: 40 mg ⁴ ; 500 mg ¹	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 Pathology CPG 7.1 Resp. Drug Guidelines 1st Ed., 2008 GI Drug Guidelines 1st Ed., 2010 ED Guidelines 2nd ed., 2008 CWMH Chemotherapy Protocols: Testicular, Gynae. Protocols 2013 CV Therap. Guidelines 3rd ed., 2015
13.2 Anticholinergics		
Oxybutinin	Tablet: 5 mg (hydrochloride) ²	
13.3 Irrigations		
Glycine	Irrigation: 1.5% (2 L) ¹	UROLOGY USE ONLY
13.4 Dialysis solution		
Peritoneal Dialysis Solution	Injection: 1.5% (2 L) ¹ Injection: 2.5% (2 L) ¹	

14 GASTROINTESTINAL MEDICINES		
14.1 Antiulcer medicines		
14.1.1 Antacids		
14.1.2 Histamine (H₂) Receptor Antagonists		
Ranitidine	Tablet: 300 mg (hydrochloride) ⁴ CONSULTANT USE ONLY Injection: 50 mg/2 mL (hydrochloride) ¹	<ul style="list-style-type: none"> • Paediatric CPG 8 • Obstetrics & Gynaecology CPGs Version 1.1, June 2014 • ICU Guideline for Clin.Mgmt. 1.4, 2010 • Antibiotic Guidelines 3rdEd., 2011 • GI Drug Guidelines 1st Ed., 2010 • Palliative Care in Paed. Oncology, 2008 • CWMH Chemotherapy Protocol CHOP: Non-Hodgkin's Lymphoma, 2013 • CWMH Chemotherapy Protocol: Ovarian Cancer (advanced), 2013
14.1.3 Proton pump inhibitors		
Omeprazole	Capsule: 20 mg ¹	<ul style="list-style-type: none"> • ICU Guideline for Clin.Mgmt. 1.4, 2010 • Antibiotic Guidelines 3rdEd., 2011 • GI Drug Guidelines 1st Ed., 2010 • CWMH Chemotherapy Protocol CHOP: Non-Hodgkin's Lymphoma, 2013
14.2 Antiemetic medicines		
Metoclopramide	Injection: 5 mg/mL (2 mL) ¹	<ul style="list-style-type: none"> • Obstetrics & Gynaecology CPGs Version 1.1, June 2014 • ICU Guideline for Clin.Mgmt. 1.4, 2010 • GI Drug Guidelines 1st Ed., 2010 • ED Guidelines 2nd ed., 2008 • HIV Care ART Guidelines 2nd ed., 2013 • CWMH Chemotherapy Protocols: Testicular, Paediatric Oncology, Haematology, Gynaecology Protocols
Ondansetron	CHEMOTHERAPY PROTOCOL USE ONLY Injection: 2 mg/mL (4 mL) (hydrochloride) ¹ Tablet: 8 mg ¹	<ul style="list-style-type: none"> • GI Drug Guidelines 1st Ed., 2010 • CWMH: Palliative Paediatric Oncology, Haematology, Gynaecology Protocols
Promethazine	Injection: 25 mg/mL (2 mL) (hydrochloride) ⁵ Oral liquid: 5 mg/5 mL (hydrochloride) (100 mL) ³ Tablet: 10 mg (hydrochloride) ⁴	<ul style="list-style-type: none"> • Obstetrics & Gynaecology CPGs Version 1.1, June 2014 • GI Drug Guidelines 1st Ed., 2010 • ED Guidelines 2nd ed., 2008 • HIV Care ART Guidelines 2nd ed., 2013 • Palliative Care in Paed. Oncology, 2008 • CWMH Chemotherapy Protocol: Ovarian Cancer (advanced), 2013

Prochlorperazine	Injection: 12.5 mg/mL (mesylate) ⁵ Tablet: 5 mg (maleate) ⁴	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 GI Drug Guidelines 1st Ed., 2010 ED Guidelines 2nd ed., 2008 HIV Care and ART Guidelines 2nd ed., 2013 CWMH Chemotherapy: Palliative Care, Surgical, Lymphoma, Gynaecological Protocols, 2013
14.3 Immunosuppressive medicines CONSULTANT USE ONLY		
Azathioprine	Tablet: 50 mg ²	<ul style="list-style-type: none"> Resp. Drug Guidelines 1st Ed., 2008 GI Drug Guidelines 1st Ed., 2010
Mercaptopurine	Tablet: 50 mg ¹	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Methotrexate	Injection: 25 mg/mL (sodium) (2 mL) ¹ Tablet: 2.5 mg (sodium) ¹	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Sulphasalazine	Tablet: 500 mg ²	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
14.4 Laxatives		
Bisacodyl	Suppository: 10 mg ⁴ Tablet: 5 mg ⁴	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010 Palliative Care in Paed. Oncology, 2008
Lactulose	Oral liquid: 3.35 g/5 mL (500 mL) ¹	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010 Palliative Care in Paed. Oncology, 2008
Paraffin	Oral liquid: 500 mL (B.P.) ⁵	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
14.5 Medicines used in diarrhoea		
14.5.1 Oral rehydration		
Oral rehydration salts	Salts for reconstitution: 5.125 g sachet for 250 mL preparation ⁵	<ul style="list-style-type: none"> Paediatric CPG 8 Antibiotic Guidelines 3rdEd., 2011
14.5.2 Supplements for diarrhoea in children		
Zinc	Dispersible Tablet: 20 mg (sulphate) ⁵	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Vitamin A (Retinol)	IMCI PROTOCOL Capsule: 50,000 International Units ⁵ ; 100,000 International Units ⁵ ; 200,000 International Units ⁵	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
14.5.3 Antimotility medicines		
Diphenoxylate + Atropine	Tablet: 2.5 mg diphenoxylate + 25 microgram atropine ⁴	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010

14.6 Anti-infective medicines in Diarrhoeal Diseases		
14.6.1 Strongyloidiasis		
Thiabendazole	Chewable Tablet: 250mg ⁴	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010 HIV Care and ART Guidelines 2nd ed., 2013
14.6.2 Worms (Helminths)		
Mebendazole	Chewable Tablet: 100 mg ⁵ IMCI PROTOCOL	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 GI Drug Guidelines 1st Ed., 2010 HIV Care and ART Guidelines 2nd ed., 2013
Pyrantel	Chewable Tablet: 250 mg (embonate) ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 GI Drug Guidelines 1st Ed., 2010
14.7 Medicines used in Complications of Liver Disease		
14.7.1 Medicines used in Hepatic Encephalopathy		
Lactulose	Oral liquid: 3.35 g/5 mL (500 mL) ¹	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
15 HORMONES, OTHER ENDOCRINE MEDICINES AND CONTRACEPTIVES		
15.1 Diagnostic agent for adrenocortical function		
Tetracosactrin	Injection: 250 mcg/mL ¹	CONSULTANT USE ONLY
15.2 Antidiuretic hormone agonist		
Desmopressin	Injection: 4 microgram/mL (acetate) ¹	PAEDIATRIC CONSULTANT USE ONLY
15.3 Medicines used in autonomic neuropathy		
Fludrocortisone	Tablet: 100 microgram ¹ *REFRIGERATE*	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012
15.4 Thyroid hormones and antithyroid medicines		
Carbimazole	Tablet: 5 mg ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
Thyroxine	Tablet: 50 microgram ³ ; 100 microgram ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
15.5 Estrogens		
Ethinylloestradiol	Tablet: 50 micrograms ¹	
15.6 Progestogens		
Medroxy-progesterone	Tablet: 10 mg ¹	USE IN SECONDARY AMENORRHEA ONLY
Norethisterone	Tablet: 5 mg ³	FOR GYNAECOLOGY CLINIC ONLY

15.7 Contraceptives		
15.7.1 Oral hormonal contraceptives		
Ethinylloestradiol + Levonogestrel + ferrous fumerate (Microgynon®)	Tablet: 30 micrograms ethinylloestradiol + 150 micrograms levonogestrel+ 75 mg ferrous fumerate ^{5a}	
Levonorgestrel	Tablet: 30 micrograms ^{5a}	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014
15.7.2 Barrier Contraceptives		
Condom	Male ⁵	<ul style="list-style-type: none"> Comprehensive Mgmt. Guidelines for STIs 2nd Ed. 11.3
15.7.3 Emergency contraceptive		
Levonorgestrel (POSTINOR®)	Tablet: 0.75 mg (Box of 2 tablets) ^{4, Hub}	
15.7.4 Injectable hormonal contraceptives		
Medroxy-progesterone	Depot Injection: 150 mg/mL (acetate) ^{5a}	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014
Norethisterone enantate	Depot Oily solution in prefilled syringe: 200 mg/mL ⁴	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014
15.7.5 Implantable contraceptives		
Etonogestrel (Implanon®)	Implant: 68 mg ⁴	
Levonorgestrel (Jadelle®)	Two implants: 75 mg (150 mg total) ⁴	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014
15.7.6 Intrauterine Devices		
Copper Intrauterine Contraceptive Device	TCu380A Intrauterine Contraceptive Device ³	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014
16 MEDICINES USED FOR DIABETES		
16.1 Insulins * REFRIGERATE*		
Biphasic isophane insulin	Injection: 100 International Units/mL (30% insulin neutral + 70 % isophane) (10 mL) ⁴	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012
Intermediate-acting isophane insulin	Injection: 100 International Units/mL (10mL) ⁴	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012
Short-acting soluble insulin	Injection : 100 International Units/mL (insulin neutral) (10 mL) ⁴	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012 ICU Guideline for Clin.Mgmt. 1.4, 2010 Paediatric CPG 8 ED Guidelines 2nd ed., 2008
16.2 Oral Medicines used to Treat Diabetes		
Glibenclamide	Tablet: 5 mg ⁴	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012

Glipizide	Tablet: 5 mg ⁴	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012
Metformin	Tablet: 500 mg ⁴	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012
16.3 Medicines for hypoglycaemia		
Glucagon	Injection kit: 1 mg ^{1, Request only}	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
16.4 Medicines used in diabetic ketoacidosis		
Mannitol	Injection: 20% (500 mL) ⁵	<ul style="list-style-type: none"> Paediatric CPG 8
Sodium Bicarbonate	Injection: 84 mg/mL (10 mL) ³	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012 Paediatric CPG 8
16.5 Medicines used in peripheral neuropathy		
Amitriptyline	Tablet: 25 mg ⁴	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012 HIV Care and ART Guidelines 2nd ed., 2013 Palliative Care in Paed. Oncology, 2008
Carbamazepine	Tablet: 200 mg ³	<ul style="list-style-type: none"> Diabetes Mgmt. Guidelines 3rd Ed. 2012 Palliative Care in Paed. Oncology, 2008
Sodium Valproate	Oral Liquid: 200 mg/5mL ² Enteric Coated Tablet: 200 mg ⁴	<ul style="list-style-type: none"> Palliative Care in Paed. Oncology, 2008
17 IMMUNOLOGICALS		
17.1 Diagnostic agents		
PPD Human Tuberculin (Mantoux)	Injection: 1 mL ³	
17.2 Sera and immunoglobulins		
Anti-D Rh(D) Immunoglobulin	Injection: 250 mcg/mL (1250 International Units) ³	<ul style="list-style-type: none"> Obstetrics and Gynaecology Clinical Practice Guidelines Version 1.1, June 2014
Hepatitis B (HBV) Immunoglobulin	Injection: 200 - 250 International Units ¹	
Normal Human Gamma globulin (IgG)	Injection: 16% / 2 mL ^{1, Request only}	
Tetanus immune globulin	Injection: 250 International Units ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
Varicella Zoster Immunoglobulin	Injection: 125 International Units ^{1, Request only}	

17.3 Vaccines

Bacillus Calmette – Guerin (BCG)	Multidose powder + solvent for injection: 1.5 mg ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Cholera	Oral liquid: 3 mL ^{Request only} (only for Suva, Lautoka, Labasa Health Ctr/office)	
Diphtheria, Tetanus and Pertussis (DTP) + Haemophilus influenzae type B vaccine (Hib) + Hepatitis B (HBV)	Injection : 0.5 mL ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Hepatitis B (HBV)	Child injection: 10 microgram ^{5a} Adult injection: 20 microgram ²	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Human Papilloma Virus ^(HPV types 16 +18)	Syringe for injection: 0.5 mL ^{Health centre and N/S only}	
Measles + Mumps + Rubella	Multi dose injection: 0.5 mL ^{5a}	
Pneumococcal 10 valent adsorbed	Injection: 0.5 mL ^{Health centre and N/S only}	
Poliomyelitis (OPV)	Oral Sabin: 0.1 mL ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Rotavirus	Oral liquid: 1.5 mL ^{Health centre and N/S only}	
Tetanus Toxoid (TT)	Injection: 0.5 mL ^{5a}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 ED Guidelines 2nd ed., 2008
Typhoid	Injection: 0.5 mL ^{Request only}	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011
Yellow Fever	Injection: 0.5 mL ^{Request only}	

18 MUSCLE RELAXANTS AND ANTICHOLINESTERASES

18.1 Muscle Relaxants

Atracurium	Injection: 25 mg/2.5 mL ¹	
Baclofen	Tablet: 10mg ²	
Diazepam	Injection: 5 mg/mL (2 mL) ^{5a} IMCI PROTOCOL	<ul style="list-style-type: none"> Paediatric Analgesia and sedation Clinical Practice Guideline ED Guidelines 2nd ed., 2008 Palliative Care in Paed. Oncology, 2008
Pancuronium	Injection: 2 mg/mL (2 mL) (bromide) ¹	
Suxamethonium	Injection: 50 mg/mL (2 mL) (chloride) ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Guidelines 2nd ed., 2008
Vecuronium	Powder for Injection: 10 mg (bromide) ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Guidelines 2nd ed., 2008

18.2 Anticholinsterases		
Neostigmine	Injection: 2.5 mg/mL ¹	
Pyridostigamine	Tablet: 60 mg ¹	MYASTHENIA GRAVIS
19 OPHTHALMOLOGICAL PREPARATIONS		
19.1 Anti-infective medicines		
19.1.1 Antibacterials		
Chloramphenicol	Eye drop: 0.5% (10 mL) ⁴ Eye ointment: 1% (4 g) ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011
Gentamicin	OPHTHALMOLOGY DEPARTMENT ONLY Eye drop: 0.3% (15 mL) ¹	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011
Neomycin + PolymyxinB + Bacitracin	Eye drop: ¹ Neomycin 5 mg Polymyxin B 500 International Units Bacitracin 400 International Units/g	
Neomycin + Polymyxin B + Dexamethasone	Eye ointment: (3.5 g) ¹ Neomycin 3.5 mg Polymyxin 10 000 International Units Dexamethasone 0.1% ¹	OPHTHALMOLOGY DEPARTMENT ONLY
Neomycin + Polymyxin B + Gramicidin	Eye ointment: ¹ Neomycin 1.75 mg Polymyxin B 10 000 International Units Gramicidin 0.025 mg	
Tetracycline	Eye Ointment: 1% (3.5 g) ⁴ IMCI PROTOCOL	<ul style="list-style-type: none"> Antibiotic Guidelines 3rdEd., 2011
19.1.2 Antivirals		
Aciclovir	Eye Ointment: 30 mg/g ¹	OPHTHALMOLOGY DEPARTMENT ONLY
19.1.3 Antifungals		
Amphotericin	Eye ointment: 3% ^{1, special request}	OPHTHALMOLOGY DEPARTMENT ONLY
19.2 Anti-inflammatory agents		
Dexamethasone	Eye drop: 0.1% (5 mL) ¹	OPHTHALMOLOGY DEPARTMENT ONLY
Prednisolone	Eye drop: 10 mg (10 mL) ¹	OPHTHALMOLOGY DEPARTMENT ONLY
19.3 Local anaesthetics and supplementary medicines		
Oxybuprocaine	Eye drop: 0.4% (MINIMS) ¹	OPHTHALMOLOGY DEPARTMENT ONLY
Hyaluronidase	Injection: 1 500 International Units ¹	OPHTHALMOLOGY DEPARTMENT ONLY
19.4 Diagnostic agents		
Fluorescein	Eye drops: 2% (1 mL) MINIMS ¹	OPHTHALMOLOGY DEPARTMENT ONLY

19.5 Miotics and antiglaucoma medicines		
19.5.1 Beta-blockers		
Timolol	EYE DEPARTMENT ONLY Eye drop: 0.25% ¹ , 0.5% (5 mL) ¹	• Ophthalmology CPG 6.1
19.5.2 Carbonic Anhydrase Inhibitors		
Acetazolamide	Injection: 500 mg ¹ Tablet: 250 mg ³	• Ophthalmology CPG 6.1
19.5.3 Parasympathetic (Cholinergic) Agonists		
Pilocarpine	OPHTHALMOLOGY DEPARTMENT ONLY Eye drop: 1%, 2% (15 mL), 4% (15 mL) ³	• Ophthalmology CPG 6.1
Acetylcholine Chloride	Intraocular injection: 20 mg ¹	OPHTHALMOLOGY DEPARTMENT ONLY
19.5.4 Hyperosmotic Agents		
Mannitol	Injection: 20% (500 mL) ⁵	• Ophthalmology CPG 6.1
19.6 Mydriatics and cycloplegia		
Atropine	OPHTHALMOLOGY DEPARTMENT ONLY Eye Drop: 1% (10 mL) (sulphate) ¹	• Antibiotic Guidelines 3 rd Ed., 2011
Homatropine	Eye drop: 2% (15 mL) ¹	OPHTHALMOLOGY DEPARTMENT ONLY
Mydracaine	Intraocular injection: No. 2 ¹	OPHTHALMOLOGY DEPARTMENT ONLY
Tropicamide	Eye drop: 0.5% (15 mL) ¹ ; 1%(10 mL) ¹	OPHTHALMOLOGY DEPARTMENT ONLY
19.7 Ocular lubricants		
Hydroxypropyl-methylcellulose	Pre-filled syringe: 20 mg/mL ¹	OPHTHALMOLOGY DEPARTMENT ONLY
19.8 Vasoconstrictors		
Naphazoline	Eye drop: 1% (15 mL) (hydrochloride) ¹	OPHTHALMOLOGY DEPARTMENT ONLY
Phenylephrine	Eye drop: 10% (MINIMS) ¹	OPHTHALMOLOGY DEPARTMENT ONLY
Phenylephrine + Prednisolone	Eye drop: 1.2 mg/mL Phenylephrine hydrochloride + 10 mg/mL Prednisolone acetate (10 mL) ¹	OPHTHALMOLOGY DEPARTMENT ONLY
20 UTEROTONICS AND ANTIUTEROTONICS		
Oxytocin	*REFRIGERATE* Injection: 10 International Units / mL ⁵	• Obstetrics and Gynaecology Clinical Practice Guidelines Version 1.1, June 2014
Ergometrine + Oxytocin	*REFRIGERATE* Injection: 500 microgram/5 International Units ³	• Obstetrics and Gynaecology Clinical Practice Guidelines Version 1.1, June 2014
Misoprostol	OBS AND GYNAE CONSULTANT ONLY Tablet: 200 microgram ¹	• Obstetrics and Gynaecology Clinical Practice Guidelines Version 1.1, June 2014

Salbutamol	CONSULTANT USE ONLY Injection: 500 microgram/mL (sulphate) ³	<ul style="list-style-type: none"> Obstetrics and Gynaecology Clinical Practice Guidelines Version 1.1, June 2014; for acute uterine relaxation
21 MEDICINES FOR MENTAL AND BEHAVIOURAL DISORDERS		
21.1 Medicines used in psychotic disorders		
Chlorpromazine	Injection: 50 mg/2 mL (hydrochloride) ^{5a} Tablet: 50 mg ³ ; 100 mg (hydrochloride) ³	<ul style="list-style-type: none"> Mental Health CPG 3.1 2009 ED Guidelines 2nd ed., 2008 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010 HIV Care ART Guidelines 2nd ed., 2013
Diazepam	Injection: 5 mg/mL (2 mL) ^{5a} Tablet: 5 mg ⁴	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 Mental Health CPG 3.1 2009 ED Guidelines 2nd ed., 2008
Droperidol	Injection: 2.5 mg/mL ¹	<ul style="list-style-type: none"> Mental Health CPG 3.1 2009 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Fluphenazine	Injection: 25 mg/mL (deconate) ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Flupenthixol	ST GILES USE ONLY Concentrated Depot Injection: 100 mg/mL (deconate) (0.5 mL) ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Haloperidol	Depot Injection: 50 mg/mL (deconate) ³ Tablet: 1.5 mg ⁴ ; 5 mg ⁴	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 Mental Health CPG 3.1 2009 ED Guidelines 2nd ed., 2008 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Lorazepam	ST. GILES HOSPITAL USE ONLY Injection: 1 mg/mL (2 mL) ² Tablet: 1 mg, 2 mg ²	<ul style="list-style-type: none"> Mental Health CPG 3.1 2009 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Midazolam	Injection: 5 mg/mL (2 mL) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
Olanzapine	ST. GILES HOSPITAL USE ONLY Tablet: 10 mg ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Risperidone	Tablet: 2 mg ³	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010

Trifluoperazine	Tablet: 1 mg ² ; 5 mg (hydrochloride) ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
21.1.1 Medicines used in Neuroleptic (Antipsychotic) Malignant Syndrome		
Bromocriptine	Tablet: 2.5 mg ¹	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
21.1.2 Medicines to Reduce Extrapyramidal effects		
Benzhexol	Tablet: 2 mg ⁴	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Benztropine	Injection: 1 mg/mL (2 mL) (mesylate) ² Tablet: 1 mg; 2 mg (mesylate) ²	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 ED Guidelines 2nd ed., 2008 Mental Health CPG 3.1 2009 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
21.2 Medicines used in mood disorders		
21.2.1 Medicines used in depressive disorders		
Amitriptyline	Tablet: 25 mg ⁴	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Doxepin	Capsule: 25 mg (hydrochloride) ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Fluoxetine	ST GILES USE ONLY Tablet: 20 mg (hydrochloride) ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Imipramine	Tablet: 25 mg (hydrochloride) ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Sertraline	Tablet: 50 mg (hydrochloride) ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
21.2.2 Medicines used in bipolar disorders		
Carbamazepine	Tablet: 200 mg ³	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Lithium	Tablet: 250 mg (carbonate) ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness Disorders 2010
Sodium Valproate	Oral Liquid: 200 mg/5mL ² Enteric Coated Tablet: 200 mg ⁴	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010

21.3 Medicines used in anxiety disorders

Alprazolam	ST GILES USE ONLY Tablet: 0.5 mg ² ; 1 mg ²	<ul style="list-style-type: none"> Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010
Diazepam	Injection: 5 mg/mL (2 mL) ^{5a} Tablet: 5 mg ⁴	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 Mental Health CPG 3.1 2009 Paediatric CPG 8 Guidelines of Drugs commonly used in treating Mental Illness & Related Disorders 2010 CWMH Chemotherapy Protocols: Testicular, Paediatric Palliative Care, Gynaecology Protocols; 2013

22 MEDICINES ACTING ON THE RESPIRATORY TRACT

22.1 Antiasthmatic and medicines for chronic obstructive pulmonary disease

22.1.1 Beta₂ receptor stimulating medicines

Salbutamol	Oral liquid: 2 mg/5 mL (sulphate) (60 mL) ⁴ Metered dose inhaler (aerosol): 100 micrograms per dose (sulphate) (200 doses) ⁴ Respirator solution for use in nebulisers: 5 mg/mL (30 mL) (sulphate) ⁵ Tablet: 4 mg (sulphate) ⁴ CONSULTANT USE ONLY Injection: 500 microgram/mL (sulphate) ³	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Asthma Care Pathway 2014 Resp. Drug Guidelines 1st Ed., 2008 ED Guidelines 2nd ed., 2008
------------	---	---

22.1.2 Anticholinergic bronchodilators

Ipratropium	Respirator Solution for use in nebulisers: 250 microgram/mL (bromide) ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Asthma Care Pathway 2014 Resp. Drug Guidelines 1st Ed., 2008 ED Guidelines 2nd ed., 2008
-------------	---	---

22.1.3 Methylxanthines

Aminophylline	Injection: 250 mg/10 mL ⁴	<ul style="list-style-type: none"> Pathology CPG 7.1 Resp. Drug Guidelines 1st Ed., 2008 ED Guidelines 2nd ed., 2008
Caffeine	Injection: 20 mg/mL (3 mL) ¹	
Theophylline	Oral Liquid: 80 mg/15 mL (500 mL) ¹ Slow Release Tablet: 300 mg ⁴	<ul style="list-style-type: none"> Resp. Drug Guidelines 1st Ed., 2008

22.1.4 Inhaled Corticosteroids		
Beclomethasone	Metered dose inhaler (aerosol): 100 microgram per dose (dipropionate) (200 doses) ⁴	<ul style="list-style-type: none"> Resp. Drug Guidelines 1st Ed., 2008
22.1.5 Other Antiasthmatic medicines		
Magnesium sulphate	Injection: 50% (2.5 g/5 mL) ³	<ul style="list-style-type: none"> ED Asthma Care Pathway 2014
23 SOLUTIONS CORRECTING WATER, ELECTROLYTE AND ACID-BASE DISTURBANCES		
23.1 Oral		
Potassium citrate	Oral liquid: 20% ^{5a}	
Potassium chloride	Oral liquid: 1 mmol/mL (100 mL) ¹ Slow Release Tablet: 600 mg ⁴	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
Sodium Polystyrene sulphonate resin (Resonium A®)	Powder: 15 g/scoop (sulfonate) (454 g) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
23.2 Parenteral		
Calcium Chloride	Injection: 10% (10 mL) ¹	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
Glucose (Dextrose)	Injectable solution: 5% (1L isotonic) ^{5a} Injectable solution: 10% (500 mL) ¹ Injectable solution: 50% hypertonic (500 mL) ^{5a}	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Guidelines 2nd ed., 2008 CWMH Chemotherapy Protocol: Cervical Cancer, 2013 Diabetes Mgmt. Guidelines 3rd Ed. 2012
Glucose (Dextrose) + Sodium Chloride	Injectable solution: 3% glucose; 0.3% sodium chloride (1 L isotonic) ^{5a}	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010 ED Guidelines 2nd ed., 2008 National Child Cancer Network Pacific Island Workstream – Osteosarcoma Guideline PI-OS 1.0, 2012
Hartmann's Solution (Compound Sodium Lactate Intravenous Infusion)	Injectable solution: 1L isotonic ^{5a}	<ul style="list-style-type: none"> Paediatric CPG 8 Resp. Drug Guidelines 1st Ed., 2008 ED Guidelines 2nd ed., 2008 CWMH Chemotherapy Protocol: Cervical Cancer, 2013
Mannitol solution	Injection: 20% (500 mL) ^{5a}	
Plasma volume expanding solution	Injectable solution: 500 mL ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008

Potassium chloride	Injection: 7.46% w/v (equivalent to K ⁺ 1 mmol/ml and Cl ⁻ 1 mmol/ml) (10 mL) ²	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008 National Child Cancer Network Pacific Island Workstream – Osteosarcoma Guideline PI-OS 1.0, 2012 Paediatric CPG 8 Diabetes Mgmt. Guidelines 3rd Ed. 2012 ICU Guideline for Clin.Mgmt. 1.4, 2010
Sodium bicarbonate	Injection: 84 mg / mL (10 mL) ³	<ul style="list-style-type: none"> ED Guidelines 2nd ed., 2008
Sodium Chloride	Injectable solution: 0.9% (20 mL ³ ; 1 L isotonic ⁵) (equivalent to Na+154 mmol/L; Cl- 154 mmol/L)	<ul style="list-style-type: none"> Paediatric CPG 8 Antibiotic Guidelines 3rd Ed., 2011 ED Guidelines 2nd ed., 2008 ICU Guideline for Clin.Mgmt. 1.4, 2010 Chemotherapy Protocols CV Therap. Guidelines 3rd ed., 2015
Water for Injection	Injectable solution: 5 mL ⁵ FOR NICU HUMIDIFIER USE ONLY Injectable solution: 100 mL ¹	
Sodium chloride	Injection: 20% (10 mL) ¹	<ul style="list-style-type: none"> ICU Guideline for Clin.Mgmt. 1.4, 2010
24 VITAMINS AND MINERALS		
Calcium carbonate	CHRONIC RENAL FAILURE PATIENTS ONLY Tablet: 500 mg ³	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Ferrous Sulphate	Tablet: 200 mg ⁵	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 GI Drug Guidelines 1st Ed., 2010
Ferrous Gluconate	Oral liquid: 200 mg/5 mL (100 mL) ⁵	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Folic Acid	Tablet: 5 mg ⁵	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 GI Drug Guidelines 1st Ed., 2010
Vitamin A (Retinol)	Capsule: 50,000 International Units ⁵ ; 100,000 International Units ⁵ ; 200,000 International Units ⁵	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Vitamin B ₁ (Thiamine)	Injection: 50 mg/ mL (2 mL) (hydrochloride) ¹ Tablet: 100 mg (hydrochloride) ¹	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 GI Drug Guidelines 1st Ed., 2010
Vitamin B ₆ (Pyridoxine)	Tablet: 25 mg ³	<ul style="list-style-type: none"> Obstetrics & Gynaecology CPGs Version 1.1, June 2014 GI Drug Guidelines 1st Ed., 2010 CWMH Chemotherapy Protocol MAYO clinic: Colorectal Cancer, 2013 Tuberculosis Guideline 2011 Antibiotic Guidelines 3rd Ed., 2011

Vitamin B ₁₂ (Hydroxocobalamin)	Injection: 1 mg/mL ⁴	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Vitamin D (Cholecalciferol)	Tablet: 50 000 International Units (equivalent to 1.25 mg) ¹	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Vitamin K (Phytomenadione)	Injection: 1mg/mL ³ ; 10 mg/mL ³	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010
Zinc Sulphate	Dispersible Tablet: 20 mg ⁵	<ul style="list-style-type: none"> GI Drug Guidelines 1st Ed., 2010 ICU Guideline for Clin.Mgmt. 1.4, 2010

25 SPECIFIC MEDICINES FOR NEONATAL CARE

25.1 Medicines administered to the neonate

Indomethacin	Injection: 1 mg/mL (sodium trihydrate) ¹	PAEDIATRIC CONSULTANT USE ONLY
--------------	--	---------------------------------------

26 MEDICINES FOR DISEASES OF JOINTS AND BONES

26.1 Medicines used for gout

Allopurinol	Tablet: 100 mg ⁴	<ul style="list-style-type: none"> Paediatric Oncology Steering Group – Acute Proliferative Leukaemia PI-APML 1 Protocol, 2008 CWMH Chemotherapy Protocols: Lymphomas and Polycythemiavera Protocols 2013
Colchicine	Tablet: 500 microgram ¹	<ul style="list-style-type: none"> CV Therap. Guidelines 3rd ed., 2015 for Pericarditis

26.2 Medicines used for bones

Bone Wax	Ointment: 2.5 g ¹	CWMH CONSULTANT USE ONLY
----------	-------------------------------------	---------------------------------

27 DENTAL MEDICINES

27.1 Ulcers

Gentian Violet (Crystal Violet)	Paint: 1% (10 mL) ⁵	IMCI PROTOCOL
------------------------------------	---------------------------------------	----------------------

27.2 Antifungal

Nystatin	Oral liquid: 100,000 International Units/mL ⁴	<ul style="list-style-type: none"> Antibiotic Guidelines 3rd Ed., 2011 HIV Care and ART Guidelines 2nd ed., 2013 Paed. Onc. Steering Group – Infection in the immunocompromised pt., 2008 Palliative Care in Paed. Oncology, 2008
----------	---	--

27.3 Anaesthetic

Prilocaine	Injection: 4% (2.2 mL) ¹	DENTAL USE ONLY
------------	--	------------------------

28 NUTRITION

Medium chain triglyceride	Oil: 500 mL ¹	INPATIENTS AND DISCHARGE ONLY
---------------------------	---------------------------------	--------------------------------------

28.1 Enteral Feeding Supplements		
Total Parenteral Nutrition	Infusion: Glucose (19%), Amino acids and electrolytes (Vamin 18 Novum®), triglycerides (Intralipid® 20%), (1540 mL) ¹	<ul style="list-style-type: none"> Paediatric CPG 8 ICU Guideline for Clin.Mgmt. 1.4, 2010
29 EAR, NOSE AND THROAT MEDICINES		
Bismuth in Iodoform	Paste: 250 g bismuth + 500 g iodoform + 250 g liquid paraffin (B.P.) ²	FOR ENT CLINIC ONLY
29.1 Ear medicines		
Carbamide Peroxide	Ear drop: 6.5% (15 mL) ⁴	
Chloramphenicol	Ear drop: 5% (5 mL) ⁵	
Clotrimazole	Ear drop: 1% ¹	ENT CLINIC ONLY
Gentamicin	Ear drop: 0.3% (10 mL) ¹	ENT CLINIC ONLY
29.2 Nasal medicines		
29.2.1 Corticosteroids		
Beclomethasone	ENT CLINIC ONLY Nasal Spray: 50 microgram/dose (as dipropionate) ¹ (200 doses)	<ul style="list-style-type: none"> Resp. Drug Guidelines 1st Ed., 2008
29.2.2 Decongestants		
Ephedrine	Nasal Drop: 0.5% (5 mL) ⁴	<ul style="list-style-type: none"> Resp. Drug Guidelines 1st Ed., 2008
Phenylephrine + Lignocaine	Nasal Spray: 5 mg/mL Phenylephrine + 50 mg/mL Lignocaine (50 mL) ¹	ENT CLINIC ONLY
29.3 Throat Medicines		
Ethanolamine	Injection: 100 mg/2 mL (loeate) ^{Request only,1}	
Lignocaine	Oral gel: 2% (200 mL) ⁴	
30 COMPOUNDING INGREDIENTS		
Compound Tragacanth	Powder: (B.P.) ³	
Glucose	Powder: 275 g (B.P.) ³	
Glycerine	Mixture: 500 mL (B.P.) ³	
Methyl Hydroxybenzoate	Powder: 100 g ³	
Propyl Hydroxybenzoate	Powder: 100 g ³	
Propylene Glycol	Liquid: 1 L ³	
Sodium Chloride	Crystals: 1 kg (B.P.) ³	

Sodium Citrate	Crystals: 1 kg (B.P.) ³	• Resp. Drug Guidelines 1st Ed., 2008
Syrup	Oral liquid: 4 L (B.P.) ³	
Talc	Powder: 1 kg (B.P.) ¹	
White Soft Paraffin	Ointment: 1 kg (B.P.) ¹	• HIV Care and ART Guidelines 2nd ed., 2013
Zinc Oxide	Ointment: ⁵	
31 MISCELLANEOUS		
Benzoin	Tincture: ¹	
ECG Electrode	Gel: 250 mL ⁴	
Ethyl chloride	Spray: 100 mL ¹	BLOOD BANK USE ONLY
Formalin	Liquid: 1 L (B.P.) ¹	
Jelly Lubricant	Jelly: 42 g ⁵	
Soda Lime	Granules: 4.5 kg ¹	

* For restricted medicines please see your pharmacy department for a restricted antimicrobial form before prescribing.

Vital Medicines List

Adrenaline	Injection: 1 mg/mL (tartrate) ^{5a}
Amlodipine	Tablet: 5 mg ⁴
Atenolol	Tablet: 50 mg ⁴
Atropine	Injection: 600 microgram/mL (sulphate) ^{5a}
Bacillus Calmette – Guerin (BCG) Vaccine	Multidose powder + solvent for injection: 1.5 mg ^{5a}
Benzhexol	Tablet: 2 mg ⁴
Benztropine	Injection: 1 mg/mL (2mL) (mesylate) ²
Benzyl penicillin(Penicillin G)	Powder for Injection: 1 mega International Unit ⁴
Carbamazepine	Tablet: 200 mg ³
Cephalothin	Powder for Injection: 1 g (sodium) ¹ RESTRICTED*
Chloral Hydrate	Oral liquid: 100 mg/mL (200mL) ¹ PAEDIATRIC USE
Chloramphenicol	Powder for Injection: 1 g ^{5a}
Cloxacillin	ALTERNATIVE IF FLUCLOXACILLIN UNAVAILABLE Powder for Injection: 500 mg (sodium) ^{5a}
Glucose (Dextrose)	Injectable solution: 5% (1 L isotonic) ^{5a}
Diazepam	Injection: 5 mg/mL (2 mL) ^{5a} IMCI PROTOCOL
Digoxin	Injection: 25 micrograms/mL (2 mL) ^{5a} Tablet: 250 microgram ⁴
DTP + Hib + HBV Vaccine	Injection : 0.5 mL ^{5a}
Dobutamine	Injection: 12.5 mg /mL (20 mL) (hydrochloride) ¹
Dopamine	Injection: 40 mg/mL (hydrochloride) (5 mL) ³
Enalapril	Tablet: 5 mg ⁴
Frusemide	Injection: 10 mg/mL (2 mL) ^{5a} Tablet: 40 mg ⁴ ; 500 mg ¹
Gentamicin	Injection: 40 mg/mL (2 mL) ^{5a}
Glipizide	Tablet: 5mg ⁴
Haloperidol	Depot Injection: 50 mg/mL (deconate) ³
Hepatitis B (HBV) Vaccine	Child injection: 10 microgram ^{5a} Adult injection: 20 microgram ²
Hepatitis B (HBV) Immunoglobulin	Injection: 200 - 250 International Units ¹
Hydralazine	Injection: 20 mg/mL ^{5a}
Hydrocortisone	Powder for Injection: 100 mg (sodium succinate) ^{5a}
Hydroxypropyl- methylcellulose	Pre-filled syringe: 20 mg/mL ¹
Biphasic isophane insulin	Injection: 100 International Units/mL (10 mL) ⁴
Intermediate-acting isophane insulin	Injection: 100 International Units/mL (10 mL) ⁴

Short-acting soluble insulin	Injection : 100 International Units/mL (10 mL) ⁴
Isoflurane	Liquid : 500 mL ¹
Lignocaine	Injection : 2% (20 mL) ⁵
Magnesium sulphate	Injection : 50% (2.5 g/5 mL) ³
Mannitol	Injection : 20% (500 mL) ⁵
Measles + Mumps + Rubella Vaccine	Multi dose injection : 0.5 mL ^{5a}
Metformin	Tablet : 500 mg ⁴
Metronidazole	Injection : 5 mg/mL (100 mL) ¹ RESTRICTED*
Midazolam	Injection : 5 mg/mL (2 mL) ¹
Morphine	Injection : 10 mg/mL (sulphate) ^{5a}
Naloxone	Injection : 400 microgram/mL (hydrochloride) ³
Neostigmine	Injection : 2.5 mg/mL ¹
Oxytocin	Injection : 10 International Units / mL ⁵ *REFRIGERATE*
Oxybuprocaine	Eye drop : 0.4% (MINIMS) ¹
Pancuronium	Injection : 2 mg/mL (2 mL) (bromide) ¹
Phenobarbitone	Injection : 200 mg/mL (sodium) ¹
Phenytoin	Tablet : 100 mg (sodium) ⁴ Injection : 50 mg/mL (sodium) (5 mL) ^{5a}
Poliomyelitis (OPV)	Oral Sabin : 0.1 mL ^{5a}
Potassium chloride	Injection : 7.46% w/v (10 mL) ²
PPD Human Tuberculin (Mantoux)	Injection : 1 mL ³
Prednisolone	Tablet : 5 mg ⁴
Salbutamol	Respirator Solution : 5 mg/mL (30 mL) (sulphate) ⁵
Sodium Chloride	Injectable solution : 0.9% (1 L isotonic) ⁵
Sodium Valproate	Oral Liquid : 200 mg/5mL ² Enteric Coated Tablet : 200 mg ⁴
Streptokinase	Powder for injection : 1.5 million units ¹ CCU USE ONLY
Suxamethonium	Injection : 50 mg/mL (2 mL) (chloride) ¹
Tetanus Toxoid (TT)	Injection : 0.5 mL ^{5a}
Thiopentone	Powder for injection : 2.5g (sodium) ¹
Tropicamide	Eye drop : 1% (10 mL) ¹
Verapamil	Injection : 2.5 mg/mL (2 mL) (hydrochloride) ³
Vitamin K (Phytomenadione)	Injection : 1 mg/mL ³
Warfarin	Tablet : 1 mg ¹ ; 3 mg ¹ ; 5 mg (sodium) ¹ (MAREVAN®)

Nursing Station Emergency Kit

Adrenaline	Injection: 1 mg/mL (tartrate) ⁵	10 ampoules
Ampicillin	Powder for Injection: 500 mg (sodium) ^{5a}	10 vials
Atropine	Injection: 600 microgram/mL (sulphate) ^{5a}	2 ampoules
Chloramphenicol	Powder for Injection: 1 g ^{5a}	10 vials
Chlorpromazine	Injection: 50 mg/2 mL (hydrochloride) ^{5a}	2 ampoules
Cloxacillin	ALTERNATIVE IF FLUCLOXACILLIN UNAVAILABLE Powder for Injection: 500mg (sodium) ^{5a}	10 vials
Diazepam	Injection: 10 mg/2mL ^{5a}	2 ampoules
Digoxin	Injection: 25 micrograms/mL (2 mL) ^{5a}	3 ampoules
Frusemide	Injection: 10 mg/mL (2 mL) ^{5a}	10 ampoules
Gentamicin	Injection: 40 mg/mL (2 mL) ^{5a}	4 ampoules
Glyceryl trinitrate	Sublingual Tablet: 600 microgram ⁵	100 tablets
Hydralazine	Injection: 20 mg/mL ^{5a}	2 ampoules
Hydrocortisone	Powder for Injection: 100mg (sodium succinate) ^{5a}	10 vials
Morphine	Injection: 10 mg/mL (sulphate) ^{5a}	2 ampoules
Oxytocin	Injection: 10 International Units / mL ⁵ REFRIGERATE	10 ampoules
Pethidine	Injection: 50 mg/mL ^{5a}	2 ampoules
Phenytoin	Injection: 50 mg/mL (sodium) (5 mL) ^{5a}	2 ampoules
Prochlorperazine	Injection: 12.5 mg/mL (mesylate) ⁵	2 ampoules
Promethazine	Injection: 25mg/mL (2 mL) (hydrochloride) ⁵	2 ampoules
Salbutamol	Respirator Solution for use in nebuliser: 5 mg/mL (30 mL) (sulphate) ⁵	5 ampoules

Medicines Information References

The following medicine references are compulsory for all Pharmacy Departments:

- The National Medicinal Products Policy of The Republic of Fiji 2013.
- The Fiji Essential Medicines List 4th Edition 2015
- Fiji Standard Treatment Guidelines – all current editions
- Australian Medicines Handbook – current edition (hard copy or e-copy).
- Australian Pharmaceutical Formulary – current edition (e-copy)
- Martindale hardcopy or e-copy
- Australian Injectable Drugs Handbook – current edition

Summary of Forms and Procedures

The following forms and procedures are summarised below.

Adverse Medicine Reaction Report

To be filled by any health care professional to report an adverse medicine reaction. Details include: patient initials, age, sex, weight, height, race, all medicines in use, date and description of the adverse medicine reaction, treatment for the reactions, outcome and any further comments. It is to be sent to the NMTC Secretary to be tabled in the next NMTC meeting.

Instructions for Application for Medicine Amendments to Existing Treatment Guidelines and Essential Medicine List Instruction form

Contains instructions for applicants to fill out the existing treatment guidelines and EML amendment application forms.

Application for Amendments to Existing Treatment Guidelines and Essential Medicine List

This form is used by the applicant via their CSN to request amendments to existing STGs and the EML and requires the applicant to fill in details such as applicant details and the proposed amendments such as title, addition, replacement or deletion and prescriber level. Applicants are required to state the indications for each medicine and attach supporting evidence and send to the NMTC Secretary who will then evaluate the evidence with other members of the NMTC and tabulated in the next NMTC meeting. If it is necessary to amend or adjust recommendations to the STG's / EML before the publication of the next edition, a circular will be distributed and changes will also be notified on the Ministry of Health and Medical Services website.

Request Form for Medicine not on the EML

This form is used by the applicant to request items to be added on the EML as the medicines are already stated in the approved standard treatment guidelines or clinical practice guidelines. The form requires the applicant to fill in their details, requested medicine details – such as strength and formulation, indications for use, duration of therapy and to attach supporting evidence for the EML listing. The form is forwarded to the Secretary of the NMTC which will then be evaluated and to be tabulated at the next NMTC meeting.

Urgent Request for Non-EML Medicine

This form is to be used by prescribers to submit an urgent request for a non-EML medicine. Details include the name, strength, formulation, indication, duration of therapy and justification for the purchase of the medicine. The form is submitted to the Principal Pharmacist at the nearest Divisional Hospital which is then forwarded to the Chief Pharmacist and NMTC Secretary via the algorithm in the Emergency Purchase Procedure for Requested Medicines not on the EML.

Emergency Purchase Procedure for Requested Medicines not on the EML

The algorithm shows the process for medicines not on the EML, indicating the people responsible and time frame for the procurement of the medicine.

Medicine Incident Report Form

This form is used to report medicine incidents such as medicine quality, incorrect prescribing, administration and dispensing; medicine not given, unable to supply, complaints and other. Details of the incident, medicine, patient category and action taken are to be recorded. The report should be completed and returned to the Principal Pharmacist at the Divisional Hospital, which is then forwarded to the NMTC secretary to be tabled at the next NMTC meeting.

Reporting Medicine/ Product complaint Guidelines

Explains the procedure of reporting medicine / product complaints in detail; what a medicine quality complaint is, how to lodge a complaint, what happens to the report and who to report to.

Medicine Quality Complaint Form

Used by health staff to report any medicine quality complaint which is then forwarded to the local Pharmacist / Pharmacy Technician in charge then to then Principal Pharmacist of the nearest Divisional Hospital / Chief Pharmacist and Secretary of the NMTC to be tabled in the next NMTC meeting. Details the name of medicine, item number, batch/lot number, expiry date, country manufactured, brand, registration number and details problem with encountered with product.

Medicine Recall Procedure

Details the Medicine Recall Procedure used at FPBS.

Medicine Recall Pro forma

Used by FPBS to inform all Fijian Pharmacies that a product recall has been initiated. Also used to inform the NMTC secretary to table the recall in the next NMTC meeting. The form details the product, item number, batch/lot, suppliers details, reasons for recall, method of return to FPBS or to supplier, the status of replacement stock, quality assurance action and results of the quality assurance test.

ADVERSE MEDICINE REACTION REPORT

(Note: Identities of Reporter, Patient and Institution will remain confidential)

Patient (Initials or National Health Number): _____

Age: _____ Sex: F M (Please circle)

Weight: _____ kg Height: _____ Race: _____

All Medicines in Use **Asterisk suspect medicine(s) include traditional medicines/ supplements/OTCs.

Medicine(s)	Daily Dosage And Route	Date Commenced	Date Ceased	Reason for Use

DESCRIPTION OF ADVERSE MEDICINE REACTION

Date of Onset: _____

Treatment for Reactions:

Outcome: PLEASE TICK

Recovered () Not recovered () Unknown () Fatal () Date of Death: ____/____/____

Comments (e.g. relevant Hx allergies, previous exposure to this medicine): _____

Reporting Person Name/Designation: _____

Institution: _____

Signature: _____ Date: _____

(MTC USE ONLY) CAUSALITY ASSESSMENT: (Please circle)
CERTAIN POSSIBLE PROBABLE UNLIKELY

Please forward form as soon as possible to: Secretary, National Medicines & Therapeutics Committee, Fiji Pharmaceutical and Biomedical Services, P.O. Box 106, Suva or Facsimile: 338 8003

INSTRUCTIONS FOR APPLICATION FOR MEDICINE AMENDMENTS TO EXISTING TREATMENT GUIDELINES & ESSENTIAL MEDICINE LIST

- ONLY USE BLUE OR BLACK PEN AND WRITE ONLY IN BLOCK LETTERS
- CHECK THE APPROPRIATE BOXES AS SHOWN ☒
- ONLY USE INTERNATIONAL NON-PROPRIETARY NAMES/GENERIC NAMES

1. APPLICANT'S DETAILS

- ☐ Ensure you clearly and legibly fill in all details required for this section, including contact details in the event that the relevant committee needs to contact you.
- ☐ By signing the form, you declare that all information provided in this application and in the documents submitted is true and correct to the best of your knowledge.

2. PROPOSED TREATMENT CHANGES

- ☐ Only one proposed Guideline amendment per application form
- ☐ Check the appropriate boxes relating to a Treatment Guideline amendment.
- ☐ Check **ALL** appropriate boxes relating to the prescriber level

3. PROPOSED INDICATION

- ☐ Carefully fill out the proposed Treatment Guideline: indication, treatment, medicine, dose, route, interval, duration
- ☐ Where an indication is not currently reflected in the STGs, a brief rationale based upon Fiji's epidemiological data must be included as an appendix.
- ☐ The evidence submitted should be from reputable sources and should include full referencing for the committee to verify.
- ☐ Indicate Level of Evidence*
- ☐ Attach supporting evidence documentation.

*Levels of Evidence for Therapeutic Studies

From the Centre for Evidence-Based Medicine, <http://www.cebm.net>.

Level	Level of evidence
1A	Systematic review (with homogeneity) of RCTs
B	Individual RCT (with narrow confidence intervals)
1C	All or none study
2A	Systematic review (with homogeneity) of cohort studies
2B	Individual Cohort study (low quality RCT, e.g. <80% follow-up)
2C	"Outcomes" research; Ecological studies
3A	Systematic review (with homogeneity) of case-control studies
3B	Individual Case-control study
4	Case series (and poor quality cohort and case-control study)
5	Expert opinion without explicit critical appraisal or based on physiology bench research or "first principles"

NOTE: Proposals for an amendment to treatments will only be considered if:

- The application form has been fully completed.
- The applicants contact details are provided.
- The proposed change with all details has been stated clearly
- The indication is clearly stated.
- There is sufficient evidence to support the proposed amendment
- You may be requested to provide further information to clarify your submission.
- Final decision to accept or reject the proposal rests with the NMTC.

Applications are accepted all year round.

This document has been adapted from the following:

WHO and Dr Majid Cehraghali 2010, 18th Expert Committee on the Selection and Use of Essential Medicines – How to develop a National Essential Medicines List, retrieved 30 July, 2014 <http://www.who.int/selection_medicines/committees/expert/18/policy/policy2/en/>

Essential Medicines List 4th Edition 2015

NMTC Approved 22 October 2014

APPLICATION FOR AMENDMENTS TO EXISTING TREATMENT GUIDELINES FOR THE ESSENTIAL MEDICINE LIST

To be completed by the Applicant

1. APPLICANT'S DETAILS

Title: _____ Name: _____

Phone: _____ Email: _____

Health Facility / CSN : _____

Date of submission: _____ Signature: _____

2. PROPOSED STANDARD TREATMENT GUIDELINE AMENDMENT

a. Guidelines Title: _____

- b. ☐ Addition
☐ Replacement
☐ Deletion

c. **Prescriber level** (tick all that apply)

- ☐ Divisional Hospitals ☐ Specialist hospitals ☐ Sub divisional hospitals
☐ Health Centres ☐ Nursing Stations ☐ Nursing Station with Medical Officer's authorisation

3. PROPOSED TREATMENT GUIDELINE NB: Only use INN (International Non-proprietary Name/ Generic names)

STG Title, Indication and Treatment or other Recommended Guidelines where no STGs (If replacement: State existing Guideline Title, Condition and Page #)	Medicine	Proposed Regimen			
		Dose	Route	Interval	Duration
1. STG Title: Indication:				Hourly	Days
2. STG Title: Indication:				Hourly	Days
3. STG Title: Indication:				Hourly	Days

<i>Evidence (Attach supporting documents)</i>	
Name of reference (eg. Title, Volume, Page Number, website)	Level of evidence*
1.	
2.	
3.	

*Levels of Evidence for Therapeutic Studies - From the Centre for Evidence-Based Medicine, <http://www.cebm.net>.

Level	Level of evidence
1A	Systematic review (with homogeneity) of RCTs / Recommendation of Reputable Professional Society
1B	Individual RCT (with narrow confidence intervals)
1C	All or one study
2A	Systematic review (with homogeneity) of cohort studies
2B	Individual Cohort study (including low quality RCT, e.g. <80% follow-up)
2C	"Outcomes" research; Ecological studies
3A	Systematic review (with homogeneity) of case-control studies
3B	Individual Case-control study
4	Case series (and poor quality cohort and case-control study)
5	Expert opinion without explicit critical appraisal or based on physiology bench research or "first principles"

NOTE: Proposals for an amendment to treatments will **only** be considered if:

- The application form has been fully completed.
- The applicants contact details are provided.
- The change with all details has been stated clearly
- The indication has been clearly stated.
- There is sufficient evidence to support the proposed amendment

*Send completed form to the **NMTC Secretary – Fiji Pharmaceutical and Biomedical Services, Fax No: 3388003***

This document has been adapted from the following:

WHO and Dr MajidCehraghali 2010, 18th *Expert Committee on the Selection and Use of Essential Medicines – How to develop a National Essential Medicines List*, retrieved 30 July, 2014

<http://www.who.int/selection_medicines/committees/expert/18/policy/policy2/en/>

NMTC Approved 22 October 2014

REQUEST FORM FOR MEDICINE NOT ON THE EML

To be completed by the Applicant

1. APPLICANT'S DETAILS

Title: _____ Name: _____

Phone: _____ Email: _____

Health Facility / CSN : _____

Date of submission: _____ Signature: _____

2. REQUESTED MEDICINE

Name of Medicine: _____

Strength & Formulation of Medicine: _____

Indication of Use: _____

Duration of Therapy: _____

<i>Evidence (Attach supporting documents)</i>	
Name of reference (eg. Title, Volume, Page Number, website)	Level of evidence*
1.	
2.	
3.	

*Levels of Evidence for Therapeutic Studies - From the Centre for Evidence-Based Medicine, <http://www.cebm.net>.

Level	Level of evidence
1A	Systematic review (with homogeneity) of RCTs / Recommendation of Reputable Professional Society
1B	Individual RCT (with narrow confidence intervals)
1C	All or one study
2A	Systematic review (with homogeneity) of cohort studies
2B	Individual Cohort study (including low quality RCT, e.g. <80% follow-up)
2C	"Outcomes" research; Ecological studies
3A	Systematic review (with homogeneity) of case-control studies
3B	Individual Case-control study
4	Case series (and poor quality cohort and case-control study)
5	Expert opinion without explicit critical appraisal or based on physiology bench research or "first principles"

Send completed form to the **NMTC Secretary – Fiji Pharmaceutical and Biomedical Services, Fax No: 3388003**

.....

NMTC Use only **Date received:** _____

Request No: _____ **Approved/ Not-Approved**

If NOT approved, reasons why: _____

If Approved:

Quantity Purchased: _____ **Cost/unit:** _____

Total Cost: _____ **Item Code:** _____

URGENT REQUEST FOR NON-EML MEDICINE

(To be filled in by REQUESTING officer)

Name of MEDICINE: _____

Strength & Formulation of MEDICINE: _____

Indication of Use: _____

Duration of Therapy: _____

Provide justification for purchase of this MEDICINE: (Please attach Literature review, diagnostic results including microbiology report, second opinion from the microbiologist, pathologist, infection control specialist etc.)

Name & Position of Requesting Officer: _____

Department: _____ Health Facility: _____

Date: _____ Signature: _____

(Send completed form to Principal Pharmacist at nearest Divisional Hospital for notification to the Chief Pharmacist and NMTC Secretary – FPBS fax No: 3388003)

NMTC / FPBS / Chief Pharmacist response


Request No: _____

Approved/ Not-Approved

If Approved, State Quantity Purchased: _____ Cost/unit: _____

Total Cost: _____ Item Code: _____

EMERGENCY PURCHASE PROCEDURE FOR REQUESTED MEDICINES NOT ON THE EML



MEDICINE INCIDENT REPORT FORM

INSTITUTION: _____

UNIT: _____

NATURE OF REPORT (Please tick and Provide Details)	1.	<input type="checkbox"/>	MEDICINE QUALITY
	2.	<input type="checkbox"/>	MEDICINE PRESCRIBED INCORRECTLY
	3.	<input type="checkbox"/>	MEDICINE ADMINISTERED INCORRECTLY
	4.	<input type="checkbox"/>	MEDICINE DISPENSED INCORRECTLY
	5.	<input type="checkbox"/>	MEDICINE NOT GIVEN
	6.	<input type="checkbox"/>	UNABLE TO SUPPLY
	7.	<input type="checkbox"/>	COMPLAINT from PATIENT/STAFF
	8.	<input type="checkbox"/>	OTHER

INCIDENT DETAILS:

MEDICINE DETAILS

Medicine: _____	Dose: _____
Strength: _____	Regimen: _____
Formulation: _____	Duration: _____

Patient Category (Please tick): Inpatients (☐) Outpatients (☐) Discharge (☐)

Action Taken:

Please submit the completed form to the Principal Pharmacist of your nearest Divisional Hospital as soon as possible. Principal Pharmacist to forward report to the NMTC Secretary, Fiji Pharmaceutical and Biomedical Services, P.O. Box 106, Suva or by facsimile 3388 003.

REPORTING MEDICINE / PRODUCT COMPLAINT GUIDELINES

All product complaints/problems should be reported in all instances where there is concern relating to the safety of a medicine or it fails to meet expectations.

What is a medicine quality complaint?

Complaint can be anything which creates a hazard or places you or your patient at risk, eg:

- Compromised sterility
 - Physical Structure Defects e.g. mouldy tablet; poor dissolution
 - Incomplete instructions
 - Poor design
 - Packaging or labelling defects
 - Sub-therapeutic Effects in comparison to time of onset of action and desired therapeutic effects
- I. DO NOT THROW THE FAULTY MEDICINE OUT, unless it is contaminated or personnel are put at risk. Place item in a specimen bag, if applicable, including packaging and batch number if available.
 - II. Contact the Chief Pharmacist or nominated person for your health facility.
 - III. Complete the Medicines Quality Complaint Report form and forward to the Chief Pharmacist.

What happens to your Report?

- Forward the completed form and product to the nominated person in your Facility.
- The report is placed on a Register with National Medicines & Therapeutics Committee and a copy forwarded to the Supplier.
- Depending on the nature of the fault a recall of that medicine may occur.
- A replenishment stock will be distributed until replacements stocks are received. The Supplier will be contacted regarding the problem.
- A report will be sent back to the unit as soon as possible and widely circulated.

Medicine Quality Complaints

It is the responsibility of the person initiating the complaint to categorize the complaint and instigate the appropriate procedure as laid out below.

In all instances the Chief Pharmacist is to be advised as soon as practicable, in order to ensure the appropriate response is taken, actioned and Pharmacist/Pharmacy Technician in Charge notified.

Wherever possible the product and packaging should be retained (except in instances of contamination or personal risk).

A Medicine Quality Complaint Report is to be completed and the FPS Chief Pharmacist advised.

MEDICINE QUALITY COMPLAINT FORM

(To be filled in by reporting officer)

Name of Medicine: _____ Item No: _____

Batch/Lot No: _____ Expiry date: _____

Country manufactured: _____ Brand: _____

Registration No. (if applicable): _____

Please state problem(s) encountered with product:

Name of reporting officer: _____ Signature: _____

Unit: _____ Health Facility: _____

Date: _____

.....
To be filled in by local Pharmacist/Pharmacy Technician In Charge

Product re-examined and tested if possible: YES NO

Comments on product quality:

Name: _____ Position: _____

Date: _____ Signature: _____

Please submit the completed form to the Principal Pharmacist of your nearest Divisional Hospital as soon as possible. Principal Pharmacist to forward report to Chief Pharmacist and NMTC Secretary, Fiji Pharmaceutical and Biomedical Services, P.O. Box 106, Suva or by facsimile 3388 003.

MEDICINE RECALL PROCEDURE

(Initiated by Chief Pharmacist)

1. Chief Pharmacist issues Product Recall notice.
 2. Notice forwarded to Clinical Managers and the Risk Manager.
 3. FPBS Warehouse Manager identifies and facilitates area/s of product use and isolates any affected stock.
 4. Risk Manager notifies the Warehouse Manager who then provide findings to the Chief Pharmacist. If appropriate, a memorandum may be issued, or copies of the recall notice placed on maxi-bins where stock is held.
 5. Any affected stock is quarantined by Infection Control Officer/Store Officer for forwarding to FPS and documentation completed.
 6. Replacement stock must be supplied by the supplier before any stock is removed from sites. Replacement stock is arranged for distribution by Warehouse Manager to appropriate health facilities, in cooperation with the Stores Officer.
- ** In the event of recall the supplier must supply an alternative equivalent for a minimum period of four to six (4 to 6) months' normal usage (FPS minimum stock level)**
- ** If all stock held within the health service division is subject to the recall, the Chief Pharmacist is to liaise with the company for immediate stock replacement. If this is not possible, an alternative supplier is sought.**

MEDICINE RECALL PRO FORMA

(FPBS USE ONLY)

A RECALL HAS BEEN INITIATED ON THE FOLLOWING:-

PRODUCT: _____ ITEM NUMBER: _____

BATCH/LOT: _____ SUPPLIER: _____

PHONE: _____ FAX: _____

REASON FOR RECALL:

METHOD OF RETURN: _____

REPLACEMENT STOCK RECEIVED: _____

COMMENTS: _____

QUALITY ASSURANCE

ACTION: _____

RESULTS OF QUALITY ASSURANCE TEST:

Name: _____

Position: _____

Date: _____

Signature: _____

(RETURN REPORT TO NMTC Secretary)

Tabled at the next National Medicines & Therapeutics Committee

Date : ____/____/____

Meeting No: _____

INDEX

- 6 – Mercaptopurine, 14
- Abacavir (ABC), 11
- Acetazolamide, 29
- Acetic Acid, 20
- Acetylcholine Chloride, 29
- Acetylcysteine, 3
- Aciclovir, 10, 28
- Actinomycin D, 15
- Adenosine, 17
- Adrenaline, 2, 17, 19, 38, 40
- Alcohol (SVR), 21
- Allopurinol, 35
- Alprazolam, 32
- Alprostadil, 19
- Amikacin, 8
- Aminophylline, 32
- Amiodarone, 17
- Amitriptyline, 26
- Amitriptyline, 31
- Amlodipine, 18, 19, 38
- Amoxycillin, 5
- Amoxycillin + Clavulanic Acid, 5
- Amphotericin, 28
- Amphotericin B, 10
- Ampicillin, 5, 40
- Anti-D Rh(D) Immunoglobulin, 26
- Aspirin, 1, 16
- Atenolol, 17, 18, 38
- Atracurium, 27
- Atropine, 1, 17, 29, 38, 40
- Azathioprine, 23
- Azithromycin, 7
- Bacillus Calmette – Guérin (BCG), 27, 38
- Baclofen, 27
- Beclomethasone, 33, 36
- Benzathine Penicillin, 4
- Benzhexol, 31, 38
- Benzoin, 37
- Benzotropine, 31, 38
- Benzyl penicillin, 4, 38
- Betamethasone, 20
- Biphasic isophane insulin, 25, 38
- Bisacodyl, 23
- Bismuth in Iodoform, 36
- Bleomycin, 15
- Bone Wax, 35
- Bromocriptine, 31
- Bupivacaine, 1
- Bupivacaine + Adrenaline, 1
- Bupivacaine + Dextrose, 1
- Calcium carbonate, 34
- Calcium Chloride, 33
- Calcium Folate, 15
- Carbamazepine, 3, 26, 31, 38
- Carbamide Peroxide, 36
- Carbimazole, 24
- Carboplatin, 14
- Cefaclor, 6
- Cefotaxime, 6
- Ceftriaxone, 6
- Cephalothin, 6, 38
- Cetrimide + Chlorhexidine, 21
- Charcoal, Activated, 3
- Chloral Hydrate, 1, 38
- Chlorambucil, 13
- Chloramphenicol, 8, 28, 36, 38, 40
- Chlorhexidine, 21
- Chlorpromazine, 30, 40
- Cholera, 27
- Ciprofloxacin, 7
- Clobetasol, 20
- Clotrimazole, 36
- Cloxacillin, 5, 38, 40
- Coal Tar, 20
- Codeine, 2
- Colaspase, 15
- Colchicine, 35
- Colistin, 8
- Compound Tragacanth, 36
- Condom, 25
- Copper Intrauterine Contraceptive Device, 25
- Cotrimoxazole, 8, 12
- Cyclophosphamide, 13
- Cytarabine, 15
- Dacarbazine, 13
- Dapsone, 9, 12
- Daunorubicin, 13
- Desferrioxamine, 3
- Desmopressin, 24
- Dexamethasone, 2, 12, 28
- Diazepam, 1, 3, 27, 30, 32, 38, 40
- Didanosine (ddl), 11
- Digoxin, 17, 38, 40
- Diphenoxylate + Atropine, 23
- Diphtheria, Tetanus and Pertussis (DTP) + Haemophilus influenzae type B vaccine (Hib) + Hepatitis B (HBV), 27, 38
- Dobutamine, 19, 38
- Dopamine, 17, 19, 38
- Doxepin, 31
- Doxorubicin, 14
- Doxycycline, 6, 12
- Droperidol, 30
- ECG Electrode, 37
- Econazole, 10, 20
- Efavirenz (EFV), 11
- Enalapril, 18, 38
- Ephedrine, 19, 36
- Ergometrine + Oxytocin, 29
- Erythromycin, 7
- Ethambutol, 9
- Ethanolamine, 36
- Ethinylestradiol, 24
- Ethinylestradiol + Levonorgestrel + ferrous fumarate, 25
- Ethosuximide, 4
- Ethyl chloride, 37
- Etonogestrel, 25
- Fentanyl, 2
- Ferrous Gluconate, 16, 34
- Ferrous Sulphate, 16, 34
- Flucloxacillin, 5

Fluconazole, 10
 Fludrocortisone, 24
 Fluorescein, 28
 Fluorouracil, 14
 Fluoxetine, 31
 Flupenthixol, 30
 Fluphenazine, 30
 Folic Acid, 16, 34
 Formalin, 37
 Frusemide, 21, 38, 40
 Fuller's Earth, 3
 Gentamicin, 6, 28, 36, 38, 40
 Gentian Violet, 35
 Glibenclamide, 25
 Glipizide, 26, 38
 Glucagon, 26
 Glucose, 36
 Glucose (Dextrose), 33, 38
 Glucose (Dextrose) + Sodium Chloride, 33
 Glutaraldehyde, 21
 Glycerine, 36
 Glyceryl trinitrate, 17, 19, 40
 Glycine, 21
 Goserelin, 15
 Griseofulvin, 10
 Haloperidol, 30, 38
 Halothane, 1
 Hammamelis, 20
 Hartmann's Solution (Compound Sodium Lactate Intravenous Infusion), 33
 Heparin, 16
 Hepatitis B (HBV), 27, 38
 Hepatitis B Immunoglobulin, 26, 38
 Homatropine, 29
 Human Papilloma Virus (HPV types 16 + 18), 27
 Hyaluronidase, 28
 Hydralazine, 18, 38, 40
 Hydrochlorothiazide, 18
 Hydrocortisone, 3, 13, 20, 38, 40
 Hydrogen Peroxide, 21
 Hydroxypropyl-methylcellulose, 29, 38

Hydroxyurea, 14
 Ibuprofen, 2
 Imipramine, 31
 Indomethacin, 2, 35
 Intermediate-acting isophane insulin, 25, 38
 Ipratropium, 32
 Iron Dextran, 16
 Isoflurane, 1, 39
 Isoniazid, 9
 Isoprenaline, 17
 Isosorbide dinitrate, 17
 Jelly Lubricant, 37
 Ketamine, 1
 Ketoconazole, 10
 Labetalol, 18
 Lactulose, 23, 24
 Lamivudine (3TC), 11
 Lamivudine + Tenofovir (TDF + 3TC), 11
 Lamivudine + Zidovudine (3TC + AZT), 11
 Lamivudine + Stavudine (3TC + d4T), 11
 Lamivudine + Stavudine + Nevirapine, 11
 Lamivudine + Tenofovir + Efavirenz (TDF + 3TC + EFV), 11
 Lamivudine + Zidovudine + Efavirenz, 12
 Lamivudine + Zidovudine + Nevirapine, 12
 Levodopa + Benserazide, 16
 Levonorgestrel, 25
 Levonorgestrel (Jadelle®), 25
 Levonorgestrel (POSTINOR®), 25
 Lignocaine, 1, 17, 20, 36, 39
 Lignocaine + Adrenaline, 1
 Lignocaine + Prilocaine (Emla®), 1
 Lithium, 31
 Lopinavir + Ritonavir (LPV/r), 11
 Lorazepam, 30
 Magnesium sulphate, 4, 18, 19, 20, 33, 39

Mannitol, 3, 15, 26, 29, 39
 Mannitol solution, 33
 Measles + Mumps + Rubella, 27, 39
 Mebendazole, 24
 Medium chain triglyceride, 35
 Medroxy-progesterone, 24, 25
 Melphalan, 13
 Mercaptopurine, 23
 Meropenem, 8
 Metformin, 26, 39
 Methadone, 2
 Methotrexate, 14, 23
 Methyl Hydroxybenzoate, 36
 Methylated Sprits, 21
 Methyl dopa, 19
 Methylene Blue, 15
 Methylprednisolone, 13
 Metoclopramide, 22
 Metronidazole, 7, 39
 Miconazole, 10
 Midazolam, 1, 4, 30, 39
 Misoprostol, 29
 Morphine, 2, 39, 40
 Mydracaine, 29
 Naloxone, 3, 39
 Naphazoline, 29
 Neomycin, 20
 Neomycin + Polymyxin B + Dexamethasone, 28
 Neostigmine, 28, 39
 Nevirapine (NVP), 11
 Nifedipine, 18
 Nitrofurantoin, 8
 Noradrenaline, 19
 Norethisterone, 24
 Norethisterone enantate, 25
 Normal Human Gamma globulin (IgG), 26
 Nystatin, 35
 Olanzapine, 30
 Omeprazole, 22
 Ondansetron, 22
 Oral rehydration salts, 23
 Oxybuprocaine, 28, 39
 Oxybutinin, 21
 Oxytocin, 29, 39, 40

Paclitaxel, 14
 Pancuronium, 27, 39
 Paracetamol, 2
 Paraffin, 23
 Peritoneal Dialysis Solution, 21
 Permethrin, 20
 Pethidine, 2, 40
 Phenobarbitone, 4, 39
 Phenoxymethyl-penicillin, 4
 Phenylephrine, 29
 Phenylephrine + Lignocaine, 36
 Phenylephrine + Prednisolone, 29
 Phenytoin, 4, 39, 40
 Pilocarpine, 29
 Piperacillin + Tazobactam, 5
 Plasma volume expanding solution, 33
 Plastic spray, 20
 Pneumococcal 10 valent adsorbed, 27
 Podophyllotoxin, 10
 Poliomyelitis (OPV), 27, 39
 Potassium chloride, 33, 34, 39
 Potassium citrate, 33
 Povidone Iodine Alcoholic, 21
 Povidone Iodine Aqueous, 21
 Povidone Iodine Scrub, 21
 PPD Human Tuberculin (Mantoux), 26, 39
 Pralidoxime, 3
 Prednisolone, 3, 13, 28, 39
 Prilocaine, 35
 Primidone, 4
 Probenacid, 9
 Procaine Penicillin, 5
 Procarbazine, 15
 Prochlorperazine, 23, 40
 Promethazine, 3, 22, 40
 Propranolol, 18
 Propyl Hydroxybenzoate, 36

Propylene Glycol, 36
 Protamine Sulphate, 16
 Psoriasis, 20
 Pyrantel, 24
 Pyrazinamide, 9
 Pyridostigmine, 28
 Quinine, 12
 Ranitidine, 22
 Rifampicin, 8, 9
 Rifampicin + Isoniazid, 9
 Risperidone, 30
 Rotavirus, 27
 Salbutamol, 3, 19, 30, 32, 39, 40
 Sertraline, 31
 Short-acting soluble insulin, 25, 39
 Silver Nitrate, 9
 Silver Sulphadiazine, 9
 Simvastatin, 19
 Soda Lime, 37
 Sodium bicarbonate, 34
 Sodium Bicarbonate, 26
 Sodium chloride, 34
 Sodium Chloride, 34, 36, 39
 Sodium Citrate, 37
 Sodium hypochlorite, 21
 Sodium Polystyrene sulphonate resin, 33
 Sodium Valproate, 26, 31, 39
 Spironolactone, 18
 Stavudine (d4T), 11
 Stop TB Kit Category I & III, 9
 Stop TB Kit Category II, 9
 Streptokinase, 16, 39
 Streptomycin, 9
 Sulphasalazine, 23
 Suxamethonium, 27, 39
 Syrup, 37
 Talc, 37
 Tamoxifen, 15
 Tenofovir (TDF), 11

Terbinafine, 10
 Tetanus immune globulin, 26
 Tetanus Toxoid (TT), 27, 39
 Tetracosactrin, 24
 Tetracycline, 28
 Theophylline, 32
 Thiabendazole, 24
 Thiopentone, 1, 39
 Thyroxine, 24
 Timolol, 29
 Total Parenteral Nutrition, 36
 Triamcinolone, 13, 20
 Trifluoperazine, 31
 Trimethoprim, 9
 Tropicamide, 29, 39
 Typhoid, 27
 Vancomycin, 8
 Varicella Zoster Immunoglobulin, 26
 Vecuronium, 27
 Verapamil, 18, 39
 VinBLAstine, 14
 VinCRistine, 15
 Vitamin A (Retinol), 23, 34
 Vitamin B₁ (Thiamine), 34
 Vitamin B₁₂ (Hydroxocobalamin), 16, 35
 Vitamin B₆ (Pyridoxine), 34
 Vitamin D (cholecalciferol), 35
 Vitamin K (Phytomenadione), 17, 35, 39
 Warfarin, 16, 39
 Water for Injection, 34
 White Soft Paraffin, 37
 Yellow Fever, 27
 Zidovudine (AZT), 11
 Zinc, 23
 Zinc Oxide, 37
 Zinc Sulphate, 35